Veterinary Drug terms — page 19 | HESTIA Glossary

Browse all 1,061 veterinary drug terms HESTIA uses to describe agricultural data — with definitions and synonyms. Free and open.

Sodium 4-aminosalicylate 4-Amino-2-hydroxybenzoic acid, Monosodium salt; Aminosalicylate sodium anhydrous [USAN]; p-Aminosalicylate sodium
Sodium arsenite Arsenenous acid, Sodium salt (1:1); Sodium arsenite; Arsenenous acid, sodium salt
Sodium azide Sodium azide (Na(N3)); Sodium azide; U-3886
Sodium citrate 2-Hydroxy-1,2,3-propanetricarboxylic acid,Trisodium salt; Citric acid, trisodium salt; CCRIS 3293
Sodium permanganate Permanganic acid (HMnO4), Sodium salt; Sodium permanganate; EINECS 233-251-1
Somatostatin Somatostatin (sheep); Somatostatin; CCRIS 3629
Soneclosan 5-Chloro-2-(4-chlorophenoxy)phenol,; Soneclosan [INN]; Snoclosan
Sparfloxacin rel-5-Amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; Sparfloxacin [USAN:INN:BAN:JAN]; AT 4140
Spectinomycin Decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-4H-pyrano[2,3-b][1,4]benzodioxin-4-one; Spectinomycin; M-141
Spermidine N1-(3-aminopropyl)-1,4-butanediamine; Spermidine; 4-04-00-01300 (Beilstein Handbook Reference)
Spermine N1,N4-Bis(3-aminopropyl)-1,4-butanediamine; spermine; 71-44-3; musculamine; neuridine; gerontine; Spermin; 4,9-Diaza-1,12-dodecanediamine; Diaminopropyltetramethylenediamine; N,N'-Bis(3-aminopropyl)-1,4-butanediamine; Spermine, puriss; 1,4-Butanediamine, N,N'-bis(3-aminopropyl)-; N,N'-Bis(3-aminopropyl)butane-1,4-diamine; 1,4-Bis(aminopropyl)butanediamine; 4,9-Diazadodecamethylenediamine; 4,9-Diazadodecane-1,12-diamine; N1,N1'-(Butane-1,4-diyl)bis(propane-1,3-diamine); UNII-2FZ7Y3VOQX; 1,4-Bis(aminopropyl) butanediamine; 1,4-Diaminobutane, N,N'-bis(3-aminopropyl)-; NSC 268508; BRN 1750791; AI3-26633; EINECS 200-754-2; MFCD00008215; 2FZ7Y3VOQX; CHEMBL23194; CHEBI:15746; 1,5,10,14-Tetraazatetradecane; PFNFFQXMRSDOHW-UHFFFAOYSA-N; 1,4-Butanediamine, N1,N4-bis(3-aminopropyl)-; NSC268508; Spermine, 97%; spermidine 3HCl; AK151116; N,N'-Bis(3-aminopropyl)-1,4-diaminobutane; S-7400; SPM; Spermina; MLS002472980; diaminopropyl-tetramethylenediamine; Spermina [Italian]; SMR001397086; Polyspermine; Spermine puriss; C10H26N4; 4,12-diamine; Spermine, >=97%; Tocris-0958; Lopac-S-2876; N1,N4-bis(3-aminopropyl)-1,4-butanediamine; Biomol-NT_000213; bmse000117; NCIMech_000206; Spermine, min. 98.0%; Lopac0_001077; SCHEMBL14965; WLN: Z3M4M3Z; GTPL710; Spermine, analytical standard; 4-04-00-01301 (Beilstein Handbook Reference); BPBio1_001086; DTXSID9058781; BDBM79403; cid_5351186; BIS2403; 1, N,N'-bis(3-aminopropyl)-; Spermine, >=99.0% (GC); ZX-AFC000644; HY-B1777; ZINC1532734; 5789AF; CCG-35276; GE1335; HSCI1_000212; KM1406; s3948; AKOS024258603; DB00127; MCULE-4079516211; NSC-268508; SDCCGSBI-0051047.P003; N1,N4-bis(3-aminopropyl)-butanediamine; NCGC00015941-01; NCGC00015941-02; NCGC00015941-03; NCGC00015941-04; NCGC00015941-05; NCGC00024902-01; NCGC00024902-02; NCGC00024902-03; AS-35114; BP-21388; CC-34521; LS-45647; NCI60_035280; DB-055526; TR-030731; CS-0013806; FT-0625219; FT-0631308; Spermine, Vetec(TM) reagent grade, >=97%; ST24048685; ST50825496; N,N''-bis(3-aminopropyl)butane-1,4-diamine; C00750; 956S569; L001114; n1,n1'-(butane-1,4-diyl)dipropane-1,3-diamine; Q424597; N,N'-Bis(3-aminopropyl)-1,4-tetramethylenediamine; N1,N1-(Butane-1,4-diyl)bis(propane-1,3-diamine); (3-aminopropyl){4-[(3-aminopropyl)amino]butyl}amine; (3-aminopropyl)({4-[(3-aminopropyl)amino]butyl})amine; N1,N1'-(Butane-1,4-diyl); bis(propane-1,3-diamine); 2B445AED-6284-43E4-82FE-39598858D67F; 3-aminopropyl-[4-(3-aminopropylamino)butyl]amine; hydrochloride; N,N''''-bis(3-aminopropyl)butane-1,4-diamine; hydrochloride; N,N''''-bis(3-azanylpropyl)butane-1,4-diamine; hydrochloride; Spermine, BioReagent, amorphous semi-solid, suitable for cell culture; 71052-31-8; Spermine; 4-04-00-01301 (Beilstein Handbook Reference)
Sporanox 4-[4-[4-[4-[[2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl)-3H-1,2,4-triazol-3-one; itraconazole; 84625-61-6; Oriconazole; Sporanox; Itrizole (TN); Sporanox (TN); ITCZ; Itraconazole (Sporanox); Itraconazol [Spanish]; cis-Itraconazole; VHVPQPYKVGDNFY-ZPGVKDDISA-N; DSSTox_CID_3180; DSSTox_RID_76908; DSSTox_GSID_23180; ITZ; A1-01739; C35H38Cl2N8O4; 1-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-4,5-dihydro-1H-1,2,4-triazol-5-one; 2-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2,4-dihydro-3H-1,2,4-triazol-3-one; 2-butan-2-yl-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; 4-(4-(4-(4-(((2R,4S)-2-((1H-1,2,4-triazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-(sec-butyl)-2,4-dihydro-3H-1,2,4-triazol-3-one; 4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-sec-butyl-1,2,4-triazol-3-one; 4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1h-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl)-3h-1,2,4-triazol-3-one; CAS-84625-61-6; 84604-65-9; Intraconazole; Sporanox(TM); NCGC00018268-03; 4-(4-{4-[4-({[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl}oxy)phenyl]piperazin-1-yl}phenyl)-2-(1-methylpropyl)-2,4-dihydro-3H-1,2,4-triazol-3-one; Itraconazole & Nyotran; Itraconazole EP Impurity E; Itraconazole (JP17/USAN); SCHEMBL23934; MLS006011958; CHEMBL22587; CHEBI:6076; DTXSID3023180; CTK8F8379; Pharmakon1600-01505756; 252964-65-1; Tox21_110854; 2485AH; AC-542; BDBM50127138; CI0042; NSC759239; s2476; AKOS015842738; AKOS015961385; Tox21_110854_1; CS-2127; DB01167; KS-1268; MCULE-2446846552; NE57775; NSC-759239; NCGC00274068-01; NCGC00274068-02; NCGC00274068-07; 873066-43-4; HY-17514; SMR001827898; Itraconazole & Nyotran(Liposomal Nystatin); SBI-0206914.P001; AB0012897; AB2000585; FT-0601621; SW219756-1; Itraconazole 2.0 mg/ml in Dimethyl Sulfoxide; D00350; EN300-122640; 24236-EP2281816A1; 24236-EP2314590A1; AB01274818-01; AB01274818_02; AB01274818_03; Q411229; BRD-A23067620-001-01-7; 2-(Butan-2-yl)-4-(4-{4-[4-({(2R,4S)-2-(2,4-dichlorophenyl)-2-[(1H-1,2,4-triazol-1-yl)methyl]-1,3-dioxolan-4-yl}methoxy)phenyl]piperazin-1-yl}phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one; 3H-1,2,4-Triazol-3-one, 4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-pipera-zinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl); 4-[4-[4-[4-[[(2R,4S)-2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazole-1-ylmethyl)-1,3-dioxolane-4-yl]methoxy]phenyl]piperazino]phenyl]-2-(1-methylpropyl)-4H-1,2,4-triazole-3(2H)-one; Itraconazole; R 51211
Stallimycin N-[5-[[(3-Amino-3-iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-4-[[[4-(formylamino)-methyl-1H-pyrrol-2-yl]carbonyl]amino]-1H-pyrrole-2-carboxamide; Stallimycin; BRN 0468437
Staurosporine (9S,10R,11R,13R)-2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; LSM-5781; (9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-11-(methylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one; Bio2_000413; BiomolKI_000006; BiomolKI2_000016; KBioGR_000486; KBioSS_000486; CHEMBL374074; SCHEMBL10026708; CHEBI:94716; KBio2_000486; KBio2_003054; KBio2_005622; KBio3_000891; KBio3_000892; Bio2_000893; IDI1_002168; NCGC00163370-01; BRD-K70549064-001-02-5; Q27166514; Staurosporine; CCRIS 3272
Streptogramins Pristinamycin; Quinupristin-Dalfopristin; Virginiamycin
Streptomycin O-2-Deoxy-2-(methylamino)-alpha-L-glucopyranosyl-(1->2)-O-5-deoxy-3-C-formyl-alpha-L-lyxofuranosyl-(1->4)-N1,N3-bis(aminoiminomethyl)-D-streptamine; Streptomycin; 4-18-00-07540 (Beilstein Handbook Reference)
Streptonigrin (4R)-5-Amino-6-(7-amino-5,8-dihydro-6-methoxy-5,8-dioxo-2-quinolinyl)-4-(2-hydroxy-3,4-dimethoxyphenyl)-3-methyl-2-pyridinecarboxylic acid; Streptonigrin; A 050165L302
Streptozocin 2-Deoxy-2-[[(methylnitrosoamino)carbonyl]amino]-D-glucose; streptozocin; STREPTOZOTOCIN; 18883-66-4; streptozosin; EstreptozociStreptozocine; Streptozocinium; Streptozocinum; alpha-Streptozocin; streptozotocin (stz); N-D-Glucosyl-(2)-N'-nitrosomethylurea; CHEBI:9288; C8H15N3O7; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; UNII-8H27GUR065; 8H27GUR065; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose; DSSTox_CID_1282; DSSTox_RID_76055; DSSTox_GSID_21282; 66395-18-4; alkylating agent; 2-Desoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; binds to D1-methyl-1-nitroso-3-((2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)urea; Zanosar (TN); SR-05000001720; 2-deoxy-2-[[(methylnitrosoamino)carbonyl]amino]-D-glucose; NCGC00016738-01; CAS-18883-66-4; Spectrum_000960; Streptozotocin - Zanosar; Prestwick3_000732; Spectrum2_000062; Spectrum3_001087; Spectrum4_001244; Spectrum5_001047; Epitope ID:134282; N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; SCHEMBL4748; CHEMBL1603; BSPBio_000684; BSPBio_002734; KBioGR_001768; KBioSS_001440; MLS004774123; DivK1c_000531; SPECTRUM1500543; SPBio_000243; BPBio1_000754; Streptozocin (JAN/USAN/INN); DTXSID2021282; BCBcMAP01_000142; HMS501K13; KBio1_000531; KBio2_001440; KBio2_004008; KBio2_006576; KBio3_001954; BIS4356; NINDS_000531; ZX-AFC000345; HMS1921A07; HMS2092I09; HMS2097C06; HMS3714C06; Pharmakon1600-01500543; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; ACT03364; ZINC3977737; Streptozocin, >=98.0% (HPLC); Tox21_110585; Tox21_201859; Tox21_302974; CCG-39870; MFCD00006607; NSC757321; s1312; AKOS025310730; Tox21_110585_1; API0015373; DB00428; NSC-757321; IDI1_000531; SMP1_000282; NCGC00178500-01; NCGC00178500-02; NCGC00178500-03; NCGC00178500-04; NCGC00178500-07; NCGC00256594-01; NCGC00259408-01; CC-34553; SMR001233317; SBI-0051517.P003; AB2000735; AB00513906; SW199198-2; C07313; D05932; 24975-EP2275420A1; 24975-EP2277858A1; 24975-EP2292227A2; 24975-EP2295053A1; 24975-EP2298767A1; 24975-EP2314574A1; 27771-EP2272827A1; 27771-EP2295055A2; 27771-EP2295416A2; 27771-EP2295426A1; 27771-EP2295427A1; 27771-EP2298748A2; 27771-EP2298764A1; 27771-EP2298765A1; 27771-EP2298778A1; 27771-EP2305642A2; 27771-EP2308833A2; 27771-EP2308861A1; 27771-EP2311453A1; 27771-EP2311842A2; 27771-EP2314587A1; 27773-EP2277858A1; 27773-EP2292227A2; 27773-EP2298767A1; 27773-EP2314587A1; AB00052092-03; AB00052092_04; AB00052092_05; 883S664; C-16594; Q257331; SR-01000939745; SR-01000939745-3; SR-05000001720-1; SR-05000001720-2; W-201687; Streptozocin, Vetec(TM) reagent grade, 98%, powder; N-(Methylnitrosocarbamoyl)-|A-D-glucosamine; Streptozotocin; Streptozocin, >=75% alpha-anomer basis, >=98% (HPLC), powder; alpha-D-Glucopyranose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-; 3-methyl-3-nitroso-1-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-3-yl]urea; STREPTOZOTOCIN; 18883-66-4; 2-Desoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 66395-18-4; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-deoxy-2-[[(methylnitrosoamino)carbonyl]amino]-D-glucose; STREPTOZOTOCIN-stereo; SCHEMBL444088; CHEMBL1651906; CTK5C4576; DTXSID90369855; ZSJLQEPLLKMAKR-YDEIVXIUSA-N; HMS3412N09; HMS3676N09; AKOS024456708; Streptozocin; U-9889
Succimer (R*,S*)-2,3-Dimercaptobutanedioic acid; Succimer; 3-03-00-01033 (Beilstein Handbook Reference)
Succinic acid Butanedioic acid; 4-02-00-01908 (Beilstein Handbook Reference)
Succinylsulphathiazole Succinyl sulfathiazole; Succinylsulfathiazole; 4-27-00-04637 (Beilstein Handbook Reference)
Sulconazole 1-[2-[[(4-Chlorophenyl)methyl]thio]-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole; Sulconazole; Sulconazol [INN-Spanish]
Sulfonamides Dihydrofolate Reductase Inhibitors/Combinations
Sulfones Aldesulfone Sodium; Dapsone
Sulphachlorpyridazine 4-Amino-N-(6-chloro-3-pyridazinyl)benzenesulfonamide; Sulfachloropyridazine; sulfachlorpyridazine; 80-32-0; 4-amino-N-(6-chloropyridazin-3-yl)benzenesulfonamide; Sulphachlorpyridazine; Nefrosul; Sulfacloropiridazina; Durasulf; N1-(6-Chloro-3-pyridazinyl)sulfanilamide; Sulfachlorpyridazinum; Sonilyn; 4-Amino-N-(6-chloro-3-pyridazinyl)benzenesulfonamide; Cluricol; Vetisulid; Vetisulid (Veterinary); Solfaclorpiridazina [DCIT]; Ba 10370; Benzenesulfonamide, 4-amino-N-(6-chloro-3-pyridazinyl)-; UNII-P78D9P90C0; CHEBI:59057; Sulfachlorpyridazinum [INN-Latin]; Sulfacloropiridazina [INN-Spanish]; EINECS 201-269-9; N1-(6-Chlor-3-pyridazinyl)sulfanilamid; MLS000777734; P78D9P90C0; CAS-80-32-0; 4-amino-N-(6-chloropyridazin-3-yl)benzene-1-sulfonamide; NCGC00016323-01; NCGC00016323-04; SMR000414174; N(1)-(6-Chloro-3-pyridazinyl)sulfanilamide; N(sup 1)-(6-Chloro-3-pyridazinyl)sulfanilamide; DSSTox_CID_25265; DSSTox_RID_80778; DSSTox_GSID_45265; [(4-aminophenyl)sulfonyl](6-chloropyridazin-3-yl)amine; 4-Amino-N-(6-chloro-pyridazin-3-yl)-benzenesulfonamide; Prinzone vet.; Solfaclorpiridazina; SCP; SR-01000773478; Cosulid; Prinzone vet; Sulfachlorpyridazine [USAN:INN]; Nefrosul (TN); Prestwick_130; Sulfachlorpyridazine [USP:INN:BAN]; Sulphachloropyridazine; Cosumix (Salt/Mix); Spectrum_000127; Prestwick0_000715; Prestwick1_000715; Prestwick2_000715; Prestwick3_000715; Spectrum2_001942; Spectrum3_001221; Spectrum4_000444; Spectrum5_001011; Epitope ID:122243; cid_6634; Ciba 10370; Oprea1_485631; SCHEMBL94138; BSPBio_000929; BSPBio_002662; KBioGR_000828; KBioSS_000587; SPECTRUM1501142; SPBio_002003; SPBio_002850; BPBio1_001023; Sulfachlorpyridazine (USP/INN); CHEMBL1443577; DTXSID9045265; BDBM90673; CTK7D7908; KBio2_000587; KBio2_003155; KBio2_005723; KBio3_002162; ZINC49140; XOXHILFPRYWFOD-UHFFFAOYSA-N; 3-sulfanilamido-6-chloropyridazine; HMS1570O11; HMS1921J11; HMS2092F19; HMS2097O11; HMS2766B06; HMS3714O11; Pharmakon1600-01501142; ALBB-011657; HY-B1781; KS-00000XU1; STR03778; Tox21_110372; Tox21_112957; BBL037369; CCG-39459; MFCD00057371; NSC757858; s3708; SBB001158; STK315422; AKOS000308728; Tox21_110372_1; CS-7970; DB11461; MCULE-9179642576; NSC-757858; NCGC00016323-02; NCGC00016323-03; NCGC00016323-09; NCGC00094909-01; NCGC00094909-02; AC-12002; AK307661; ST007536; N'-(6-Chloro-3-pyridazinyl)sulfanilamide; SBI-0051655.P002; AB0151335; LS-177518; TR-044943; AB00052217; FT-0674699; R1866; D05948; AB00052217_11; Sulfachloropyridazine 100 microg/mL in Methanol; Sulfachloropyridazine 1000 microg/mL in Methanol; SR-01000773478-2; SR-01000773478-3; Sulfachloropyridazine 100 microg/mL in Acetonitrile; W-104238; 4-amino-N-(6-chloro-3-pyridazinyl)-benzenesulfnamide; 4-Amino-N-(6-chloropyridazin-3-yl)-benzenesulfonamide; BRD-K32021043-001-05-1; Q27126423; 4-Amino-N-(6-chloro-3-pyridazinyl)benzenesulfonamide #; 4-azanyl-N-(6-chloranylpyridazin-3-yl)benzenesulfonamide; Pyridazin-3-amine, N-(4-aminophenylsulfonyl)-6-chloro-; Sulfachloropyridazine, VETRANAL(TM), analytical standard; Sulfachlorpyridazine, United States Pharmacopeia (USP) Reference Standard; N'-[(5Z)-7,7-dimethyl-3-oxo-2,6,7,8-tetrahydrocinnolin-5(3H)-ylidene]-N,N-dimethylhydrazonoformamide; Sulfachlorpyridazine; EINECS 201-269-9
Sulphaclozine 4-Amino-N-(6-chloro-2-pyrazinyl)benzenesulfonamide; Sulfaclozine; 102-65-8; 4-amino-N-(6-chloropyrazin-2-yl)benzenesulfonamide; UNII-69YP7Z48CW; Sulfaclozine [INN]; 69YP7Z48CW; Sulfaclozine (INN); Q-201758; Sulphachlorpyrazine sodium; Sulfaclozina; Sulfaclozinum; Sulfachlorpyrazin; Sulfaclozinum [INN-Latin]; Sulfaclozina [INN-Spanish]; Sulfaclozin; EINECS 203-044-0; N1-(6-Chlor-2-pyrazinyl)sulfanilamid; SCHEMBL2109909; ZINC2091; CHEMBL2105493; KS-00001DEF; DTXSID60144515; s4898; AKOS015896008; CS-5127; QC-6937; NCGC00183279-01; HY-19285; N(sup 1)-(6-Chloropyrazinyl)sulfanilamide; FT-0659201; D08537; A800596; 4-amino-N-(6-chloro-2-pyrazinyl)benzenesulfonamide; Q27264391; 4-azanyl-N-(6-chloranylpyrazin-2-yl)benzenesulfonamide; Benzenesulfonamide, 4-amino-N-(6-chloro-2-pyrazinyl)-; Sulfaclozine; EINECS 203-044-0
Sulphadiazine 4-Amino-N-2-pyrimidinylbenzenesulfonamide; sulfadiazine; 68-35-9; Sulphadiazine; Sulfapyrimidine; Sulfadiazin; Sulfazine; Sulfadiazene; Adiazine; Adiazin; Debenal; Liquadiazine; Sulfapyrimidin; Pyrimal; 2-Sulfanilamidopyrimidine; Cremodiazine; Spofadrizine; Theradiazine; Cremotres; Deltazina; Diazolone; Eskadiazine; Microsulfon; Neotrizine; Palatrize; Piridisir; Quadetts; Quadramoid; Sanodiazine; Sterazine; Sulfatryl; Sulfolex; Sulfonsol; Terfonyl; Trifonamide; Truozine; Diazin; Neazine; Pirimal; Sulfose; Trisem; Sulfanilamidopyrimidine; Honey diazine; Lipo-Levazine; Tri-Sulfameth; Triple Sulfas; Coco-Diazine; Lipo-Diazine; Metha-Meridiazine; Sulfadiazinum; Diazovit; Sulfadiazina; Sulphadiazine E; Sulfapirimidin; Di-Azo-Mul; Thi-Di-Mer; 2-Sulfanilylaminopyrimidine; Codiazine; Silvadene; Pecta-diazine, suspension; Benzenesulfonamide, 4-amino-N-2-pyrimidinyl-; Solfadiazina [DCIT]; RP 2616; 4-amino-N-(pyrimidin-2-yl)benzenesulfonamide; Pyrimidine, 2-sulfanilamido-; Sulfapyrimidin [German]; 2-Sulfapyrimidine; N(1)-2-pyrimidylsulfanilamide; 4-amino-N-pyrimidin-2-ylbenzenesulfonamide; N(1)-2-pyrimidinylsulfanilamide; Sulfadiazinum [INN-Latin]; Sulfadiazina [INN-Spanish]; 4-AMINO-N-2-PYRIMIDINYLBENZENESULFONAMIDE; Zinc Sulfadiazine; 2-Sulfanilamidopyrimidin [German]; S.N. 112; A 306; A-306 (VAN); N(sup 1)-2-Pyrimidinylsulfanilamide; Thermazene; Sildaflo; CHEBI:9328; Sulfanilamide, N(sup 1)-2-pyrimidinyl-; N(sup1)-2-Pyrimidylsulfanilamide; Sulfanilamide, N1-2(1H)-pyrimidinylidene-; 4-Amino-N-(2-pyrimidinyl)benzenesulfonamide; 4-amino-N-pyrimidin-2-yl-benzenesulfonamide; Sulfanilamide, N1-2-pyrimidinyl-; UNII-0N7609K889; A-306; N(sup1)-2-Pyrimidinylsulfanilamide; EINECS 200-685-8; MFCD00006065; NSC 35600; 4-amino-N-(pyrimidin-2-yl)benzene-1-sulfonamide; CHEMBL439; BRN 0235192; C10H10N4O2S; AI3-01047; S. N. 112; SEEPANYCNGTZFQ-UHFFFAOYSA-N; NSC35600; NSC-35600; CAS-68-35-9; NCGC00016305-01; Solfadiazina; CocoDiazine; silver sulfadiazine; 0N7609K889; [(4-aminophenyl)sulfonyl]pyrimidin-2-ylamine; 2-Sulfanilamidopyrimidin; NSC117870; 141582-64-1; SMR000059113; Sulfadiazine (TN); N-(2-Pyrimidinyl)sulfanilamide; Sulfadiazine [USAN:INN:JAN]; rBPI21 & Sulfa; N1-(Pyrimidin-2-yl)sulfanilamide; SR-01000002973; 547-32-0; SSD; 2-Sulfanilamido-pyrimidine; diazine; CRL-8131 & Sulfadiazine; N1-2-Pyrimidinylsulfanilamide; Sulfadiazine (JAN/USP/INN); Sulfadiazine,(S); Trisulfapyrimidine, oral suspension; Sulfadiazine [USP:INN:BAN:JAN]; Prestwick_428; Spectrum_000986; Sulfadiazina Reig Jofre; Sulfacombin (Salt/Mix); Prestwick0_000023; Prestwick1_000023; Prestwick2_000023; Prestwick3_000023; Spectrum2_001319; Spectrum3_001362; Spectrum4_000342; Spectrum5_000992; Epitope ID:140083; N1-2-Pyrimidylsulfanilamide; Sulfadiazine, >=99.0%; DSSTox_CID_24130; DSSTox_RID_80105; DSSTox_GSID_44130; Oprea1_081078; SCHEMBL24176; BSPBio_000085; BSPBio_002884; KBioGR_000743; KBioSS_001466; 5-25-10-00067 (Beilstein Handbook Reference); MLS000069423; MLS006011457; DivK1c_000543; SPECTRUM1500546; SPBio_001417; SPBio_002006; BPBio1_000095; WLN: T6N CNJ BMSWR DZ; DTXSID7044130; CTK7D7930; HMS501L05; KBio1_000543; KBio2_001466; KBio2_004034; KBio2_006602; KBio3_002104; NINDS_000543; HMS1568E07; HMS1921A13; HMS2090P09; HMS2092I15; HMS2095E07; HMS2235D19; HMS3371L19; HMS3655I10; HMS3712E07; Pharmakon1600-01500546; ZINC120319; ALBB-014888; BCP12140; HY-B0273; N(1)-(2-Pyrimidinyl)sulfanilamide; Tox21_110360; BBL013169; BDBM50166571; CCG-39257; NSC757324; Recombinant bactericidal/permeability-increasing protein & Sulfadiazine; s1770; SBB007604; SBB057674; STK317797; 2-(p-Aminobenzenesulfonamido)pyrimidin; AKOS000119073; CS-2263; DB00359; KS-1144; MCULE-4577338719; NE10425; NSC-757324; Sulfadiazin 100 microg/mL in Methanol; 2-(4-Aminobenzenesulfonamido)pyrimidine; 4-amino-N-2-pyrimidylbenzenesulfonamide; IDI1_000543; NCGC00016305-02; NCGC00016305-03; NCGC00016305-04; NCGC00016305-05; NCGC00016305-06; NCGC00016305-10; NCGC00023291-03; NCGC00023291-04; SULFADIAZINE (TRISULFAPYRIMIDINES); 2-(4-Aminobenzenesulfonylamino)pyrimidine; AC-26817; AK321973; H458; ST059447; Sulfanilamide, N1-2-pyrimidinyl- (8CI); 4-amino-N-2-pyrimidinyl benzenesulfonamide; Mixture of sulfadiazine, and sulfamethazine; SBI-0051520.P003; AB2000282; LS-147838; 4-[[(Pyrimidin-2-yl)amino]sulfonyl]aniline; AB00052095; Benzenesulfonamide,4-amino-N-2-pyrimidinyl-; FT-0674741; R3929; S0579; ST51006797; SW196657-3; 4-amino-N-(2-pyrimidinyl) benzenesulfonamide; 4-Amino-N-(2-pyrimidinyl)benzenesulfonamide #; 68S359; C07658; D00587; Trisulfapyrimidine, oral suspension (Salt/Mix); AB00052095-13; AB00052095-14; AB00052095_15; AB00052095_16; Benzenesulfonamide, 4-amino-N-(2-pyrimidinyl)-; Sulfadiazine, VETRANAL(TM), analytical standard; Q-201759; Q2555060; SR-01000002973-2; SR-01000002973-3; BRD-K32273377-001-05-4; BRD-K32273377-001-09-6; F1657-1720; Sulfadiazine, certified reference material, TraceCERT(R); Z271004844; Sulfadiazine, European Pharmacopoeia (EP) Reference Standard; Sulfadiazine, United States Pharmacopeia (USP) Reference Standard; 4-Amino-N-(2-pyrimidinyl)benzenesulfonamide, N1-(Pyrimidin-2-yl)sulfanilamide; Sulfadiazine, Pharmaceutical Secondary Standard; Certified Reference Material; Sulfadiazine for identification of impurity F, European Pharmacopoeia (EP) Reference Standard; Sulfadiazine; A 306
Sulphadimethoxine 4-Amino-N-(2,6-dimethoxy-4-pyrimidinyl)benzenesulfonamide; sulfadimethoxine; Sulphadimethoxine; 122-11-2; Sulfadimethoxydiazine; Sulfadimethoxin; Sulfadimetoxin; Albon; Dimetazina; Sulfadimetoxina; Agribon; Deposul; Sulfadimethoxinum; 4-Amino-N-(2,6-dimethoxy-4-pyrimidinyl)benzenesulfonamide; 4-amino-N-(2,6-dimethoxypyrimidin-4-yl)benzenesulfonamide; Arnosulfan; Bactrovet; Diasulfa; Diasulfyl; Dimethoxysulfadiazine; Madribon; Madrigid; Madriqid; Madroxin; Madroxine; Maxulvet; Memcozine; Metoxidon; Neostrepal; Persulfen; Roscosulf; Scandisil; Sulfastop; Sulfoplan; Theracanzan; Dinosol; Dorisul; Omnibon; Radonin; Redifal; Sudine; Sulxin; Symbio; Abcid; Fuxal; Sulfadimetossina; 2,6-Dimethoxy-4-sulfanilamidopyrimidine; 2,4-Dimethoxy-6-sulfanilamido-1,3-diazine; 6-Sulfanilamido-2,4-dimethoxypyrimidine; Benzenesulfonamide, 4-amino-N-(2,6-dimethoxy-4-pyrimidinyl)-; Agribon (TN); Abcid (TN); 2,6-Dimethoxy-4-(p-aminobenzenesulfonamido)pyrimidine; Rofenaid; Primor; Solfadimetossina [DCIT]; UNII-30CPC5LDEX; Sulfadimetossina [Italian]; NSC 683544; Sulfadimethoxinum [INN-Latin]; Sulfadimetoxina [INN-Spanish]; CHEBI:32161; EINECS 204-523-7; N1-(2,6-Dimethoxy-4-pyrimidinyl)sulfanilamide; 30CPC5LDEX; BRN 0306856; MLS000069720; ZZORFUFYDOWNEF-UHFFFAOYSA-N; N(1)-(2,6-dimethoxy-4-pyrimidinyl)sulfanilamide; NSC683544; N(sup 1)-(2,6-Dimethoxy-4-pyrimidinyl)sulfanilamide; 4-Amino-N-(2,6-dimethoxy-4-pyrimidinyl)benzolsulfonamid; Sulfanilamide, N(sup 1)-(2,6-dimethoxy-4-pyrimidinyl)-; NCGC00016375-01; CAS-122-11-2; SMR000017367; Solfadimetossina; DSSTox_CID_3607; DSSTox_RID_77105; DSSTox_GSID_23607; Sulfadimetoxine; Neostreptal; [(4-aminophenyl)sulfonyl](2,6-dimethoxypyrimidin-4-yl)amine; Suldixine; Sulfabon; Di-Methox; SULFAMED-G; Benzenesulfonamide, 4-amino-N-(2,6-dimethoxy-4-pyrimidinyl)-, monosodium salt; Sulfadimethoxine [JAN]; SR-01000000227; Sulfdimethoxine; Ultrasulfon; Lasibon; Mecozine; Sumbio; Sdmo; CCRIS 9326; Prestwick_979; Rofenaid (Salt/Mix); Spectrum_001408; Sulfadimethoxine [USP:INN:BAN:JAN:NF]; Benzenesulfonamide, 4-amino-N-(2,6-dimethoxy-4-pyrimidinyl)-, sodium salt (1:1); Opera_ID_1856; Prestwick0_000728; Prestwick1_000728; Prestwick2_000728; Prestwick3_000728; Spectrum2_001419; Spectrum3_001454; Spectrum4_000442; Spectrum5_001221; CBKinase1_000256; CBKinase1_012656; Epitope ID:122237; Cambridge id 5251398; Oprea1_486812; Oprea1_495206; SCHEMBL93845; Sulfadimethoxine (JAN/USP); BSPBio_000656; BSPBio_002947; KBioGR_000824; KBioSS_001888; 5-25-13-00290 (Beilstein Handbook Reference); MLS000103402; MLS000104965; MLS001148602; CHEMBL62193; DivK1c_000088; SPECTRUM1501144; SPBio_001498; SPBio_002595; ARONIS018062; BPBio1_000722; component of Prazil (Salt/Mix); component of Primor (Salt/Mix); DTXSID1023607; HMS500E10; KBio1_000088; KBio2_001888; KBio2_004456; KBio2_007024; KBio3_002447; 4-Sulfa-2,6-dimethoxypyrimidine; component of Maxutrim (Salt/Mix); component of Rofenaid (Salt/Mix); NINDS_000088; 4-amino-N-(2,6-dimethoxypyrimidin-4-yl)benzene-1-sulfonamide; HMS1570A18; HMS1921J15; HMS2090P11; HMS2092F21; HMS2097A18; HMS2230L05; HMS3370K02; HMS3655H05; HMS3714A18; Pharmakon1600-01501144; component of Trivalbon (Salt/Mix); BCP15413; HY-B0337; KS-00004AC0; Tox21_110405; BBL023015; CCG-38972; MFCD00057345; NSC757860; s1962; SBB001275; STK018258; ZINC13233295; AKOS000485038; Tox21_110405_1; API0004264; CS-2379; DB06150; KS-5335; MCULE-5924558211; NSC-683544; NSC-757860; 4-Sulfanilamido-2,6-dimethoxypyrimidine; IDI1_000088; KS-00000Z01; SMP2_000079; 2,4-Dimethoxy-6-Sulfanilamidopyrimidine; NCGC00016375-02; NCGC00016375-03; NCGC00016375-04; NCGC00016375-05; NCGC00016375-06; NCGC00016375-09; NCGC00016375-10; NCGC00024020-03; NCGC00024020-04; AC-10998; AK323646; CC-34609; M932; ST007535; SBI-0051656.P002; AB0015456; AB1004582; BB0273640; LS-147775; 6-Sulfanilamido-2,4-dimethoxy-1,3-diazine; AB00052219; B3301; FT-0603324; S0359; Sulfadimethoxine 1000 microg/mL in Methanol; SW149624-4; T7352; 2,4-Dimethoxy-6-sulfanilamido-1,3-pyrimidine; 22S112; D01142; AB00052219-15; AB00052219-17; AB00052219_18; AB00052219_19; A804847; C-19228; J-004764; Q4921678; SR-01000000227-2; SR-01000000227-4; Sulfadimethoxine, VETRANAL(TM), analytical standard; Sulfanilamide, N1-(2,6-dimethoxy-4-pyrimidinyl)-; 4-(p-Aminobenzenesulfonamido)-2,6-dimethoxypyrimidine; BRD-K71125014-001-05-7; BRD-K71125014-001-07-3; BRD-K71125014-001-17-2; N(Sup1)-(2,6-Dimethoxy-4-pyrimidinyl)sulfanilamide; F1443-4783; Sulfadimethoxine, analytical standard, >=98.5% (TLC); 4-azanyl-N-(2,6-dimethoxypyrimidin-4-yl)benzenesulfonamide; 4-amino-N-[2,6-bis(methyloxy)pyrimidin-4-yl]benzenesulfonamide; Sulfadimethoxine, European Pharmacopoeia (EP) Reference Standard; Sulfadimethoxine, United States Pharmacopeia (USP) Reference Standard; Sulfadimethoxine for peak identification, European Pharmacopoeia (EP) Reference Standard; Sulfadimethoxine; 5-25-13-00290 (Beilstein Handbook Reference)
Sulphadoxine 4-Amino-N-(5,6-dimethoxy-4-pyrimidinyl)benzenesulfonamide; SULFADOXINE; 2447-57-6; Sulphadoxine; Sulforthomidine; Sulphormethoxine; Fanasil; 4-amino-N-(5,6-dimethoxypyrimidin-4-yl)benzenesulfonamide; Sulfadoxin; SulfadoxiSulfadoxinum; Fanzil; Ro 4-4393; Solfadossina [DCIT]; 4-Sulfanilamido-5,6-dimethoxypyrimidine; Sulfadoxinum [INN-Latin]; Benzenesulfonamide, 4-amino-N-(5,6-dimethoxy-4-pyrimidinyl)-; Sulfadoxina [INN-Spanish]; 4-Amino-N-(5,6-dimethoxy-4-pyrimidinyl)benzenesulfonamide; WR 4873; N'-(5,6-Dimethoxy-4-pyrimidyl)sulfanilamide; UNII-88463U4SM5; 6-(4-Aminobenzenesulfonamido)-4,5-dimethoxypyrimidine; EINECS 219-504-9; N1-(5,6-Dimethoxy-4-pyrimidinyl)sulfanilamide; Sulfadoxine (Sulphadoxine); BRN 0625453; CHEBI:9329; SolfadossiSulformethoxine; Sulformetoxine; PJSFRIWCGOHTNF-UHFFFAOYSA-N; N(sup 1)-(5,6-Dimethoxy-4-pyrimidinyl)sulfanilamide; 88463U4SM5; NCGC00016612-01; Orthosulfin; Sulphormetoxin; CAS-2447-57-6; DSSTox_CID_3608; DSSTox_RID_77106; DSSTox_GSID_23608; Sulphorthodimethoxine; 4-amino-N-(5,6-dimethoxypyrimidin-4-yl)benzene-1-sulfonamide; 4-amino-N-[5,6-bis(methyloxy)pyrimidin-4-yl]benzenesulfonamide; SR-05000001523; Sulfadoxine [USAN:INN:BAN:JAN]; Sulfadoxine (JAN/USP/INN); Sanasil: Sulfadoxine: Sulformetoxin; Ro-4-4393; WR 4073; Sulfadoxine [USAN:USP:INN:BAN:JAN]; Prestwick0_001094; Prestwick1_001094; Prestwick2_001094; Prestwick3_001094; CHEMBL1539; SCHEMBL41069; BSPBio_001168; 5-25-13-00306 (Beilstein Handbook Reference); MLS002154150; SPBio_003054; BPBio1_001286; ZINC2094; Sulfadoxin, >=95% (TLC); DTXSID6023608; GTPL10173; HMS1571K10; HMS2090P07; HMS2094C19; HMS2098K10; HMS2230E05; HMS3371I15; HMS3715K10; Pharmakon1600-01506086; HY-B0439; KS-00000YG8; Tox21_110523; BBL023187; MFCD00792890; NSC759319; Ro-44393; s2511; STL356042; AKOS015897281; Sulfadoxin 100 microg/mL in Methanol; Tox21_110523_1; AC-8428; CCG-213610; CS-2545; DB01299; KS-5334; MCULE-4025355907; NSC-759319; WR-4073; NCGC00016612-02; NCGC00016612-04; NCGC00016612-05; AK162164; H937; J21.373J; LS-31247; SC-62311; SMR000857259; SBI-0206941.P001; AB0013372; AB1009462; DB-046463; AB00514044; FT-0603610; N1-5,6-Dimethoxy-4-pyrimidinylsulfanilamide; S0899; ST24043251; T7564; 47S576; C07630; D00580; J10275; Sulfadoxin, VETRANAL(TM), analytical standard; AB00514044-06; AB00514044_07; AB00514044_08; A817328; Q411557; SR-05000001523-1; SR-05000001523-3; W-107313; BRD-K55250441-001-03-1; BRD-K55250441-001-06-4; Sulfadoxin, certified reference material, TraceCERT(R); 4-Amino-N-(5,6-dimethoxy-4-pyrimidinyl)benzenesulfonamide; 4-azanyl-N-(5,6-dimethoxypyrimidin-4-yl)benzenesulfonamide; Sulfadoxine, European Pharmacopoeia (EP) Reference Standard; Sulfadoxine, United States Pharmacopeia (USP) Reference Standard; 2247-57-6; 4-Amino-N-(5,6-dimethoxy-4-pyrimidinyl)benzenesulfonamide; 4-Sulfanilamido-5,6-dimethoxypyrimidine; 6-(4-Aminobenzenesulfonamide)-4,5-dimethoxypyrimidine; Sulforthomidine; Sulformethoxine; Sulfadoxine; 5-25-13-00306 (Beilstein Handbook Reference)
Sulphaguanidine 4-Amino-N-(aminoiminomethyl)benzenesulfonamide; sulfaguanidine; 57-67-0; Sulfaguanidin; Sulphaguanidine; Sulfaguine; Guanicil; Sulfanilguanidine; Sulfoguanidine; Sulfaguanil; Sulfanilylguanidine; Sulfoguanil; Sulfoguanyl; Abiguanil; Guanidan; Sulfentidine; Aterian; Guamide; Orgaguanidon; Sulfaguanidinum; Sulfoguenil; Sulfoquanidine; Ganidan; N1-Amidinosulfanilamide; Resulfon; Suganyl; Diacta; Ruocid; Sulgin; N-Guanylsulfanilamide; S-Guanidine; 1-Sulfanilylguanidine; Sulfaguanidina; Shigatox; Guanidine, sulfanilyl-; p-Aminobenzenesulfonylguanidine; p-Aminobenzenesulfoguanidide; Sulginum; RP 2275; 2-(4-aminophenyl)sulfonylguanidine; Benzenesulfonamide, 4-amino-N-(aminoiminomethyl)-; Sulfanilamide, n(sup1)-amidino-; 4-Amino-N-(aminoiminomethyl)benzenesulfonamide; ((p-Aminophenyl)sulfonyl)guanidine; ((4-Aminophenyl)sulfonyl)guanidine; 1-((p-Aminophenyl)sulfonyl)guanidine; Solfaguanidina [DCIT]; Sulfaguamidine; 4-Amino-N-(diaminomethylene)benzenesulfonamide; A-307; Sulfanilamide, N1-amidino-; N-p-Aminobenzenesulphonylguanidine monohydrate; Sulfaguanidinum [INN-Latin]; N(sup 1)-Guanylsulfanilamide; Sulfaguanidina [INN-Spanish]; 4-Aminobenzenesulfonylguanidine; UNII-15XQ8043FN; N(sup 1)-Amidinosulfanilamide; 4-amino-N-[amino(imino)methyl]benzenesulfonamide; C7H10N4O2S; 4-amino-N-carbamimidoylbenzenesulfonamide; Emerin (pharmaceutical) (VAN); Sulfaguanidine [INN]; Emerin (pharmaceutical); EINECS 200-345-9; NSC 14041; Benzenesulfonamide, 4-amino-N-(diaminomethylene)-; N(sup 1)-(Diaminomethylene)sulfanilamide; AI3-01048; CHEMBL338802; BRBKOPJOKNSWSG-UHFFFAOYSA-N; {[amino(imino)methyl]amino}(4-aminophenyl)dioxo-lambda~6~-sulfane; 15XQ8043FN; 1-(4-aminophenyl)sulfonylguanidine; Sulfanilamide, N(sup 1)-amidino-; 2-(4-aminobenzenesulfonyl)guanidine; N-(4-aminobenzenesulfonyl)guanidine; Sulfaguanidine (INN); Sulfaguanidine, 98%; CAS-57-67-0; NCGC00016252-01; Solfaguanidina; amino[(4-aminophenyl)sulfonyl]carboxamidine; 4-Amino-N-carbamimidoylbenzene-1-sulfonamide; 4-Amino-N-diaminomethylene-benzenesulfonamide; DSSTox_CID_3609; 4-amino-N-(diaminomethylidene)benzenesulfonamide; DSSTox_RID_77107; DSSTox_GSID_23609; [(p-Aminophenyl)sulfonyl]guanidine; [(4-Aminophenyl)sulfonyl]guanidine; 1-[(p-Aminophenyl)sulfonyl]guanidine; Sulfanilyl guanadine; N1-Guanylsulfanilamide; SR-01000000167; N(sup1)-Guanylsulfanilamide; N(sup1)-Amidinosulfanilamide; Sulphanguanidine; Sulfaguanidine [INN:BAN:NF]; 4-Amino-N-guanylbenzenesulfonamide; Ulfaguanidine,(S); Prestwick_429; 2-sulfanilylguanidine; Spectrum_001412; N1-Guanidylsulfanilamide; N-1-Amidinosulfanilamide; WLN: ZR DSWMYZUM; 6190-55-2; Prestwick0_000010; Prestwick1_000010; Prestwick2_000010; Prestwick3_000010; Spectrum2_001420; Spectrum3_001456; Spectrum4_000429; Spectrum5_001197; SCHEMBL93639; SCHEMBL93640; 4-aminophenylsulfonylguanidine; BSPBio_000019; BSPBio_002951; KBioGR_000758; KBioSS_001892; MLS000069712; DivK1c_000633; SPECTRUM1501146; SPBio_001500; SPBio_001940; ARONIS018061; BPBio1_000021; DTXSID1023609; CHEBI:94621; CTK5B2717; CTK8E2965; HMS501P15; KBio1_000633; KBio2_001892; KBio2_004460; KBio2_007028; KBio3_002451; KS-00004ABZ; NINDS_000633; HMS1568A21; HMS1921J19; HMS2092H05; HMS2095A21; HMS3652J05; HMS3712A21; Pharmakon1600-01501146; 4-Amino-N-amidinobenzenesulfonamide; HY-B1267; KS-000048IC; NSC14041; ZINC3873927; Sulfanilamide, N1-amidino- (8CI); Tox21_110329; BDBM50027795; CCG-38973; MFCD00038136; NSC-14041; NSC757861; s4175; SBB006522; STK031666; STK064640; AKOS000121440; AKOS000319495; Sulfanilamide, N1-(diaminomethylene)-; Tox21_110329_1; CS-4677; DB13726; MCULE-9682829853; NE10932; NSC-757861; IDI1_000633; SMP1_000283; NCGC00018234-01; NCGC00018234-02; NCGC00018234-03; NCGC00018234-04; NCGC00018234-05; NCGC00018234-07; NCGC00024191-03; NCGC00024191-04; 61116-95-8; AC-10943; AK546787; H464; SMR000058191; ST057626; SBI-0051658.P002; SBI-0051658.P003; LS-147738; TR-049555; TX-010926; AB00052220; S0464; SW196658-2; D02437; AB00052220_15; AB00052220_16; 4-amino-N-(amino-imino-methyl)-benzenesulfonamide; 8R-0841; Q414886; Sulfaguanidine, VETRANAL(TM), analytical standard; 1N-amino(imino)methyl-4-amino-1-benzenesulfonamide; SR-01000000167-2; SR-01000000167-3; SR-01000000167-4; W-105451; 4-amino-N-[(E)-amino(imino)methyl]benzenesulfonamide; 4-amino-N-[(Z)-amino(imino)methyl]benzenesulfonamide; Z56758608; 1-Amino-4-(([amino(imino)methyl]amino)sulfonyl)benzene #; Sulfaguanidine, European Pharmacopoeia (EP) Reference Standard; Sodium 4-amino-N-(2,6-dimethoxy-4-pyrimidinyl)benzenesulfonamide; 2-[(dioxidosulfanyl)amino]-1,9-dihydro-6H-purin-6-one[sulfaguanine]; 4-Amino-N-(aminoiminomethyl)benzenesulfonamide; 4-Amino-N-guanylbenzenesulfonamide; Sulfaguanidine; A-307
Sulphamerazine 4-Amino-N-(4-methyl-2-pyrimidinyl)benzenesulfonamide; sulfamerazine; 127-79-7; Sulphamerazine; Sulfamethyldiazine; Sulfamerazin; Cremomerazine; Methylsulfazine; Sulfameradine; Mebacid; Metilsulfadiazin; 2-Sulfa-4-methylpyrimidine; Methylpyrimal; Metilsulfazin; Sulfamerazina; Sulfamerazinum; Kelamerazine; Percoccide; Pyralcid; Septacil; Septosyl; Solumedin; Sumedine; Mesulfa; Romezin; Veta-Merazine; 4-amino-N-(4-methylpyrimidin-2-yl)benzenesulfonamide; Debenal-M; Pirimal-M; Pyrimal M; Methylsulfazin; N-(4-Methyl-2-pyrimidyl)sulfanilamide; Benzenesulfonamide, 4-amino-N-(4-methyl-2-pyrimidinyl)-; 2-(Sulfanilamido)-4-methylpyrimidine; 2-(4-Aminobenzenesulfonamido)-4-methylpyrimidine; 2643-RP; RP 2632; Solfamerazina [DCIT]; Sulfamerazinum [INN-Latin]; N1-(4-Methyl-2-pyrimidinyl)sulfanilamide; Sulfamerazina [INN-Spanish]; (p-Aminobenzolsulfonyl)-2-amino-4-methylpyrimidin; A-310; 4-Amino-N-(4-methyl-2-pyrimidinyl)-benzenesulfonamide; 2-Sulfanilamido-4-methylpyrimidine; UNII-UR1SAB295F; N(1)-(4-Methyl-2-pyrimidinyl)sulfanilamide; NSC 27259; C11H12N4O2S; 4-Amino-N-(4-methyl-2-pyrimidinyl)benzenesulfonamide; CHEBI:102130; 2632 R. P.; Sulfanilamide, N1-(4-methyl-2-pyrimidinyl)-; EINECS 204-866-2; 2-(p-Aminobenzolsulfonamido)-4-methylpyrimidine; N(sup 1)-(4-Methyl-2-pyrimidinyl)sulfanilamide; BRN 0249133; UR1SAB295F; AI3-08026; MLS000551747; 4-amino-N-(4-methylpyrimidin-2-yl)benzene-1-sulfonamide; (p-Aminobenzolsulfonyl)-2-amino-4-methylpyrimidin [German]; Solfamerazina; QPPBRPIAZZHUNT-UHFFFAOYSA-N; MFCD00023212; Sulfanilamide, N(sup 1)-(4-methyl-2-pyrimidinyl)-; NCGC00016386-01; CAS-127-79-7; SMR000145672; DSSTox_CID_3612; DSSTox_RID_77109; DSSTox_GSID_23612; 4-Amino-N-(4-methyl-pyrimidin-2-yl)-benzenesulfonamide; 4-amino-N-(4-methylpyrimidin-2-yl); Sulfamerazine (INN); Sulfamerazine [USAN:INN:BAN]; SR-01000684857; [(4-aminophenyl)sulfonyl](4-methylpyrimidin-2-yl)amine; Susfamerazine; Sulfamerazine [USP:INN:BAN]; Prestwick_17; RP2632; Spectrum_000003; Opera_ID_988; Prestwick0_000694; Prestwick1_000694; Prestwick2_000694; Prestwick3_000694; Spectrum2_001320; Spectrum3_001363; Spectrum4_000343; Spectrum5_001413; 2(p-Aminobenzolsulfonamido)-4-methylpyrimidin; CHEMBL438; Epitope ID:122236; N(sup1)-(4-Methyl-2-pyrimidinyl)sulfanilamide; SCHEMBL33999; BSPBio_000847; BSPBio_002886; KBioGR_000745; KBioSS_000343; 5-25-10-00167 (Beilstein Handbook Reference); MLS001201765; DivK1c_000563; SPECTRUM1500547; SPBio_001419; SPBio_002768; BPBio1_000933; DTXSID0023612; HMS501M05; KBio1_000563; KBio2_000343; KBio2_002911; KBio2_005479; KBio3_002106; ZINC57501; NINDS_000563; 4-Amino-N-(4-methyl-2-pyrimidinyl)-benzenesulfonamide (9CI); HMS1570K09; HMS1921A15; HMS2092I17; HMS2097K09; HMS2234D16; HMS3374K04; HMS3652I03; HMS3714K09; Pharmakon1600-01500547; ALBB-025702; HY-B0512; KS-00000Z2J; NSC27259; Tox21_110411; BBL003544; CCG-39258; NSC-27259; NSC757325; s3132; SBB057970; STK520614; AKOS005143010; Tox21_110411_1; CS-2720; DB01581; KS-5323; MCULE-7699685177; NSC-757325; IDI1_000563; NCGC00016386-02; NCGC00016386-03; NCGC00016386-06; NCGC00094787-01; NCGC00094787-02; Sulfamerazine 100 microg/mL in Methanol; AK390512; H548; N'-(4-Methyl-2-pyrimidyl) sulfanilamide; SULFAMERAZINE (TRISULFAPYRIMIDINES); SBI-0051521.P003; Sulfamerazine 1000 microg/mL in Methanol; 2632 R. P; DB-041873; LS-147821; Sulfamerazine, ReagentPlus(R), >=99.0%; AB00052096; FT-0631745; FT-0645132; R1483; ST45028776; SW196334-3; Sulfamerazine, Vetec(TM) reagent grade, 98%; 2-(p-Aminobenzosulfonamido)-4-methylpyrimidine; D02435; AB00052096-13; AB00052096_15; AB00052096_16; A805747; Q415196; Sulfamerazine, VETRANAL(TM), analytical standard; Q-201761; SR-01000684857-2; SR-01000684857-4; 4-azanyl-N-(4-methylpyrimidin-2-yl)benzenesulfonamide; BRD-K93524252-001-05-6; BRD-K93524252-001-15-5; Sulfanilamide, N1-(4-methyl-2-pyrimidinyl)- (8CI); F2190-0484; Sulfamerazine, European Pharmacopoeia (EP) Reference Standard; Sulfamerazine, United States Pharmacopeia (USP) Reference Standard; Sulfamerazine, Pharmaceutical Secondary Standard; Certified Reference Material; Sulfamerazine; A-310
Sulphameter 4-Amino-N-(5-methoxy-2-pyrimidinyl)benzenesulfonamide; sulfameter; 651-06-9; 5-Methoxysulfadiazine; Sulfamethoxydiazine; Sulfametoxydiazine; Sulfamethoxine; Sulfametin; Sulphamethoxydiazine; Sulfamethoxypyrimidine; Sulfametorine; Sulphameter; 4-amino-N-(5-methoxypyrimidin-2-yl)benzenesulfonamide; Methoxypyrimal; Sulfamethoxydin; Berlicid; Sulla; Ultrax; Sulfa-5-methoxypyrimidine; Sulfamethorine; Longasulf; Supramid; BayreDaireDurenat; Juvoxin; Kinecid; Kirocid; Kiron; SolfametossidiaziSulfametoxipirimidine; Sulfametinum; AHR-857; 2-Sulfanilamido-5-methoxypyrimidine; 5-Methoxy-2-sulfanilamidopyrimidine; Sulfamethoxydiazin; SulfametoxidiaziBayer 5400; Sulfametoxydiazinum; 4-Amino-N-(5-methoxy-2-pyrimidinyl)benzenesulfonamide; Sulfameter [USAN]; Benzenesulfonamide, 4-amino-N-(5-methoxy-2-pyrimidinyl)-; 2-(4-Aminobenzenesulfonamido)-5-methoxypyrimidine; 2-Sulfanilamido-5-methoxypyrimidin; sulfamethoxidiazine; Solfametossidiazina [DCIT]; SH 613; NSC 683528; Sulfameter (Bayrena); Sulfametoxydiazinum [INN-Latin]; UNII-3L179F09D6; Sulfametoxidiazina [INN-Spanish]; EINECS 211-480-8; I-2586; N(sup 1)-(5-Methoxy-2-pyrimidinyl)sulfanilamide; BRN 0621130; N1-(5-Methoxy-2-pyrimidinyl)sulfanilamide; 2-Sulfanilamido-5-methoxypyrimidin [German]; CHEBI:53727; Sulfameter (USAN); NSC683528; Sulfanilamide, N(sup 1)-(5-methoxy-2-pyrimidinyl)-; 3L179F09D6; NCGC00016530-01; AK126667; CAS-651-06-9; Sulfametoxydiazine (INN); Sulfametoxydiazine [INN]; DSSTox_CID_3613; N(1)-(5-Methoxy-2-pyrimidinyl)sulfanilamide; DSSTox_RID_77110; DSSTox_GSID_23613; W-104807; Benzenesulfonamide, 4-amino-N-(5-methoxy-2-pyridimidinyl)-; Sulfameter(Bayrena); SR-01000721917; [(4-aminophenyl)sulfonyl](5-methoxypyrimidin-2-yl)amine; Sulfametorinum; Sulfametoxidine; Sulfamethoxydine; Prestwick_1048; Sulfameter(Bayrena)/; Sulla (TN); Spectrum_001149; 18179-67-4; Prestwick0_000769; Prestwick1_000769; Prestwick2_000769; Prestwick3_000769; Spectrum2_001428; Spectrum3_001463; Spectrum4_000426; Spectrum5_000981; 2-Sulfa-5-methoxypyrimidine; Oprea1_482593; SCHEMBL79417; BSPBio_000818; BSPBio_002985; KBioGR_000752; KBioSS_001629; 5-25-12-00525 (Beilstein Handbook Reference); MLS000069640; BIDD:GT0693; DivK1c_000468; SPECTRUM1501155; SPBio_001536; SPBio_002757; BPBio1_000900; CHEMBL1200359; DTXSID5023613; GPTONYMQFTZPKC-UHFFFAOYSA-; HMS501H10; KBio1_000468; KBio2_001629; KBio2_004197; KBio2_006765; KBio3_002485; KS-00000GAF; ZINC49142; 4-amino-N-(5-methoxypyrimidin-2-yl)benzene-1-sulfonamide; GPTONYMQFTZPKC-UHFFFAOYSA-N; NINDS_000468; HMS1570I20; HMS1921L15; HMS2092J03; HMS2097I20; HMS2233B12; HMS3374J11; HMS3655A11; HMS3714I20; Pharmakon1600-01501155; Sulphanilamide p-methoxy pyrimidine; HY-B0213; Tox21_110478; ABP000630; CCG-38965; MFCD00006067; NSC757874; s1618; SBB057653; AKOS015897255; Sulfameter 100 microg/mL in Methanol; Tox21_110478_1; API0004272; CS-2158; DB06821; MCULE-7934329522; NSC-683528; NSC-757874; IDI1_000468; NCGC00016530-02; NCGC00016530-03; NCGC00016530-04; NCGC00016530-06; NCGC00016530-07; NCGC00094915-01; NCGC00094915-02; AC-19932; AS-13912; CC-21973; K058; SC-13276; SMR000058215; ST007538; N1-(5-Methoxypyrimidin-2-yl)sulfanilamide; SBI-0051665.P002; AB0007999; AB2000165; AX8013105; DB-054761; LS-147812; AB00052227; FT-0632748; ST51006758; SW197118-3; 51S069; D02517; Sulfameter, VETRANAL(TM), analytical standard; AB00052227-11; AB00052227_12; AB00052227_13; A834976; C-17636; SR-01000721917-2; SR-01000721917-3; BRD-K87492696-001-05-8; BRD-K87492696-001-09-0; Q15410181; 4-azanyl-N-(5-methoxypyrimidin-2-yl)benzenesulfonamide; Z1522567176; 4-amino-N-[5-(methyloxy)pyrimidin-2-yl]benzenesulfonamide; Benzenesulfonamide, 4-amino-N-(5-methoxy-2-pyridimidinyl)- (9CI); InChI=1/C11H12N4O3S/c1-18-9-6-13-11(14-7-9)15-19(16,17)10-4-2-8(12)3-5-10/h2-7H,12H2,1H3,(H,13,14,15); Sulfameter; I-2586
Sulphamethazine 4-Amino-N-(4,6-dimethyl-2-pyrimidinyl)benzenesulfonamide; sulfamethazine; Sulfadimidine; 57-68-1; Sulfadimethyldiazine; Sulfamezathine; Sulphamethazine; Sulfadimerazine; Sulphamezathine; Sulfadimezine; Sulphadimidine; 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide; Sulfadimethylpyrimidine; Sulphadimethylpyrimidine; Sulfadimesin; Sulfadimesine; Sulfadimezin; Sulfadimidin; Sulfametazyny; Sulfamethiazine; Sulphamethasine; Sulphamidine; Sulphodimezine; Sulfadine; Cremomethazine; Sulfadimidina; Sulfadimidinum; Sulfametazina; Sulfodimezine; Azolmetazin; Dimezathine; Intradine; Kelametazine; Pirmazin; Spanbolet; Sulfodimesin; Superseptil; Superseptyl; Vertolan; Diazil; Mermeth; Neasina; Neazina; Sulfa-Isodimerazine; Dimidin-R; Hava-Span; Sulfadimezinum; Metazin; Calfspan Tablets; Sa III; 4,6-Dimethyl-2-sulfanilamidopyrimidine; 2-Sulfanilamido-4,6-dimethylpyrimidine; SulfaSURE SR Bolus; Sulka S Boluses; N-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide; 4,6-Dimethylsulfadiazine; 4-Amino-N-(4,6-dimethyl-2-pyrimidinyl)benzenesulfonamide; Diazil (the sulfanilamide); Primazin; Solfadimidina [DCIT]; 2-(p-Aminobenzenesulfonamido)-4,6-dimethylpyrimidine; Sulfametazyny [Polish]; Benzenesulfonamide, 4-amino-N-(4,6-dimethyl-2-pyrimidinyl)-; N(1)-(4,6-Dimethyl-2-pyrimidinyl)sulfanilamide; 4-Amino-N-(2,6-dimethyl-4-pyrimidinyl)benzenesulfonamide; A-502; 6-(4'-Aminobenzol-sulfonamido)-2,4-dimethylpyrimidin; N(1)-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide; NCI-C56600; Sulfadimidinum [INN-Latin]; Sulfadimidina [INN-Spanish]; Sulfametazina [Italian]; Sulfadimidine [INN:BAN]; (p-Aminobenzolsulfonyl)-2-amino-4,6-dimethylpyrimidin; Sulmet; BN 2409; CCRIS 3701; Sulfamethazine (USP); Sulfamethazine [USP]; UNII-48U51W007F; 2-(4-Aminobenzenesulfonamido)-4,6-dimethylpyrimidine; HSDB 4157; CHEBI:102265; EINECS 200-346-4; MFCD00006066; NSC 67457; BRN 0261304; N(sup 1)-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide; N(sup 1)-(4,6-Dimethyl-2-pyrimidinyl)sulfanilamide; Sulfanilamide, N(sup1)-(4,6-dimethyl-2-pyrimidinyl)-; AI3-26817; MLS000069711; 4-Amino-N-(4,6-dimethyl-pyrimidin-2-yl)-benzenesulfonamide; Solfadimidina; 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzene-1-sulfonamide; (p-Aminobenzolsulfonyl)-2-amino-4,6-dimethylpyrimidin [German]; 6-(4'-Aminobenzol-sulfonamido)-2,4-dimethylpyrimidin [German]; ASWVTGNCAZCNNR-UHFFFAOYSA-N; n(sup1)-(2,6-Dimethylpyrimid-4-yl)sulfanilamide; N(Sup1)-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide; NSC67457; Sulfadimidine-d4; Sulfanilamide, N1-(4,6-dimethyl-2-pyrimidinyl)-; N(Sup1)-(4,6-Dimethyl-2-pyrimidinyl)sulfanilamide; NSC683529; Sulfanilamide, N(1)-(4,6-dimethyl-2-pyrimidinyl)-; 48U51W007F; Sulfanilamide, N(sup1)-(2,6-dimethyl-4-pyrimidinyl)-; Sulfamethazine, 99%; NCGC00018243-07; [(4-Aminophenyl)sulfonyl](4,6-dimethylpyrimidin-2-yl)amine; SMR000017409; DSSTox_CID_1290; DSSTox_RID_76062; DSSTox_GSID_21290; SMZ; Sulfanilamide, N(sup 1)-(4,6-dimethyl-2-pyrimidinyl)-; Sulfamidine; CAS-57-68-1; Sulfamezathine (TN); Sulfadimidine (INN); 1020719-82-7; sulfamethazone; Diazilsulfadine; Calfspan; Panazin; Sulka k boluses; S-Dimidine; Dimidim-R; Sulfadimidine,(S); 4-Amino-N-(4,6-dimethyl-2-pyrimidyl)benzenesulfonamide; Sentry aq mardel biospheres maracyn plus; Spectrum_000990; HC210279; 4-amino-N-(4; Opera_ID_1374; Prestwick0_000775; Prestwick1_000775; Prestwick2_000775; Prestwick3_000775; Spectrum2_001321; Spectrum3_001700; Spectrum4_000344; Spectrum5_001270; Sulfamethazine, >=99%; CHEMBL446; Epitope ID:122238; Cambridge id 5251384; Sulfadimidine; Sulfadimerazine; NCIOpen2_003489; BIDD:PXR0093; Oprea1_142608; Oprea1_677935; BSPBio_000850; BSPBio_003260; CBDivE_012932; KBioGR_000747; KBioSS_001470; 5-25-10-00250 (Beilstein Handbook Reference); MLS000103403; MLS001077331; MLS002454449; DivK1c_000293; SCHEMBL151305; SPECTRUM1500548; SPBio_001441; SPBio_002789; ARONIS018080; BPBio1_000936; DTXSID6021290; ASWVTGNCAZCNNR-UHFFFAOYSA-; CTK7D7927; HMS500O15; KBio1_000293; KBio2_001470; KBio2_004038; KBio2_006606; KBio3_002480; KS-00004ACI; ZINC57494; NINDS_000293; HMS1921A17; HMS2092I19; HMS3652K03; Pharmakon1600-01500548; BCP28439; HY-B0035; KS-00000KN9; Tox21_110847; Tox21_202221; Tox21_303006; BBL005404; CCG-39259; LS-232; NSC-67457; NSC757326; s3133; SBB030487; STK097514; AKOS000119894; Tox21_110847_1; CS-2722; DB01582; MCULE-7831442410; MS-1576; NSC-683529; NSC-757326; IDI1_000293; NCGC00018243-01; NCGC00018243-02; NCGC00018243-03; NCGC00018243-04; NCGC00018243-05; NCGC00018243-06; NCGC00018243-08; NCGC00018243-09; NCGC00021490-03; NCGC00021490-04; NCGC00021490-05; NCGC00021490-06; NCGC00256371-01; NCGC00259770-01; Sulfadimidine solution, 1 mg/mL in H2O; WLN: T6N CNJ BMSWR DZ& D1 F1; AC-16126; AK481349; H462; SC-19602; ST011913; Sulfamethazine 100 microg/mL in Methanol; Sulfanilamide,6-dimethyl-4-pyrimidinyl)-; SBI-0051522.P003; SULFAMETHAZINE (TRISULFAPYRIMIDINES); AB1009296; Sulfamethazine 1000 microg/mL in Methanol; FT-0655603; N1-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide; S0586; SW219689-1; T7747; Benzenesulfonamide,6-dimethyl-4-pyrimidinyl)-; Sulfamethazine 100 microg/mL in Acetonitrile; C19530; D02436; N1-(4,6-Dimethyl-2-pyrimidinyl)sulfanilamide; AB00052097_12; AB00052097_13; SR-01000000211; Sulfamethazine, Vetec(TM) reagent grade, >=99%; Sulfamethazine, VETRANAL(TM), analytical standard; Q3976823; SR-01000000211-3; W-105450; BRD-K11640013-001-02-6; BRD-K11640013-236-03-6; 2-(4-Aminobenzenesulfonylamino)-4,6-dimethylpyrimidine; F1443-4796; N(1)-(4,6-Dimethyl-2-pyrimidinyl)sulfanilamide sulfadimidine; Sulfadimidine, European Pharmacopoeia (EP) Reference Standard; (4-AMINO-N-(4,6-DIMETHYL-2-PYRIMIDINYL)BENZENE SULFONAMIDE; 4-amino-N~1~-(4,6-dimethyl-2-pyrimidinyl)-1-benzenesulfonamide; HSDB 4157; HSDB 4157; HSDB 4157; Sulfadimidine; Sulfadimerazine; Sulfamethazine, United States Pharmacopeia (USP) Reference Standard; Sulfamethazine solution; N(1)-(4,6-Dimethyl-2-pyrimidinyl)sulfanilamide; Sulfadimidine for peak identification, European Pharmacopoeia (EP) Reference Standard; InChI=1/C12H14N4O2S/c1-8-7-9(2)15-12(14-8)16-19(17,18)11-5-3-10(13)4-6-11/h3-7H,13H2,1-2H3,(H,14,15,16); Sulfamethazine; A-502
Sulphamethizole 4-Amino-N-(5-methyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide; sulfamethizole; 144-82-1; Sulfamethizol; Sulphamethizole; Rufol; Sulfamethylthiadiazole; Proklar; Sulfamethizolum; Sulfametizol; Sulfurine; Thiosulfil; 4-Amino-N-(5-methyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide; Sulfapyelon; Urolucosil; Ayerlucil; Lucosil; Methazol; Microsul; Renasul; Salimol; Sulfstat; Tetracid; Thidicur; Ultrasul; Urocydal; Urodiaton; Urosulfin; Famet; Uroz; Sulfa gram; Thiosulfil Forte; Solfametizolo [DCIT]; Sulfametizol [INN-Spanish]; Sulfamethizolum [INN-Latin]; Thiosulfil-A-Forte; Benzenesulfonamide, 4-amino-N-(5-methyl-1,3,4-thiadiazol-2-yl)-; RP 2145; VK 53; CCRIS 756; CHEBI:9331; 2-(p-Aminobenzenesulfonamido)-5-methylthiadiazole; C9H10N4O2S2; HSDB 4379; UNII-25W8454H16; 2-Methyl-5-sulfanilamido-1,3,4-thiadiazole; 2-Sulfanilamido-5-methyl-1,3,4-thiadiazole; 5-Methyl-2-sulfanilamido-1,3,4-thiadiazole; Sulfamethizole (Proklar); EINECS 205-641-1; N1-(5-Methyl-1,3,4-thiadiazol-2-yl)sulfanilamide; CHEMBL1191; AI3-50149; MLS000028603; N(sup 1)-(5-Methyl-1,3,4-thiadiazol-2-yl)-sulfanilamide; Solfametizolo; VACCAVUAMIDAGB-UHFFFAOYSA-N; 4-Amino-N-(5-Methyl-1,3,4-Thiadiazol-2-Yl)Benzene-1-Sulfonamide; N(sup 1)-(5-Methyl-1,3,4-thiadiazol-2-yl)sulfanilamide; NCGC00016407-05; NCGC00016407-08; CAS-144-82-1; SMR000058666; 25W8454H16; DSSTox_CID_3615; DSSTox_RID_77111; DSSTox_GSID_23615; Sulfanilamide, N(sup 1)-(5-methyl-1,3,4-thiadiazol-2-yl)-; Sulfamethizole [USAN:INN:JAN]; Thiosulfil (TN); SR-01000003158; sulphamethazole; sulphamethiozole; [(4-aminophenyl)sulfonyl](5-methyl(1,3,4-thiadiazol-2-yl))amine; Prestwick_114; Sulfamethizole [USP:INN:BAN:JAN]; Spectrum_000992; Opera_ID_1595; Prestwick0_000742; Prestwick1_000742; Prestwick2_000742; Prestwick3_000742; Spectrum2_001322; Spectrum3_000570; Spectrum4_000640; Spectrum5_001078; Epitope ID:122233; SCHEMBL26453; BSPBio_000724; BSPBio_001960; KBioGR_001260; KBioSS_001472; MLS002303066; DivK1c_000141; SPECTRUM1500549; SPBio_001443; SPBio_002663; BPBio1_000798; N(1)-(5-Methyl-1,3,4-thiadiazol-2-yl)sulfanilamide; DTXSID5023615; CTK8B3741; HMS500H03; KBio1_000141; KBio2_001472; KBio2_004040; KBio2_006608; KBio3_001460; ZINC57493; NINDS_000141; Sulfamethizole (JP17/USP/INN); HMS1570E06; HMS1921A19; HMS2092I21; HMS2097E06; HMS2233L09; HMS3371A13; HMS3655F05; HMS3714E06; Pharmakon1600-01500549; HY-B0333; KS-000014AV; Tox21_110425; Tox21_201035; 2735AH; ANW-43072; BDBM50295558; CCG-39260; LS-853; NSC757327; s1957; SBB058179; AKOS002666345; Tox21_110425_1; API0004271; CS-2375; DB00576; MCULE-8287230974; NSC-757327; IDI1_000141; SMP1_000284; NCGC00016407-01; NCGC00016407-02; NCGC00016407-03; NCGC00016407-04; NCGC00016407-06; NCGC00016407-07; NCGC00016407-09; NCGC00016407-11; NCGC00024107-03; NCGC00024107-04; NCGC00024107-05; NCGC00258588-01; Sulfamethizol 100 microg/mL in Methanol; ABA-10163325; AS-10177; SC-62410; SBI-0051523.P003; AB2000390; TR-043817; AB00052098; B2039; S0360; ST51015120; SW196425-3; C08050; D00870; AB00052098_15; AB00052098_16; Sulfamethizole, VETRANAL(TM), analytical standard; J-008011; Q3976824; SR-01000003158-2; SR-01000003158-3; Sulfamethizole, analytical standard, >=99% (HPLC); BRD-K31682896-001-05-9; BRD-K31682896-001-15-8; Sulfamethizole, European Pharmacopoeia (EP) Reference Standard; 4-amino-N-(5-methyl[1,3,4]thiadiazol-2-yl)-benzenesulfonamide; 4-amino-n-[5-methyl-1,3,4-thiadiazol-2-yl]-benzenesulfonamide; benzenesulfonamide,4-amino-n-(5-methyl-1,3,4-thiadiazol-2-yl)-; Sulfamethizole, United States Pharmacopeia (USP) Reference Standard; 4-oxo-3-phenyl-10-oxa-3-aza-tricyclo[5.2.1.0*1,5*] dec-8-ene-6-carboxylic acid; Sulfamethizole; AI3-50149
Sulphamethoxazole 4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamide; sulfamethoxazole; 723-46-6; Sulphamethoxazole; Gantanol; Sulfisomezole; Sulfamethoxazol; Metoxal; Sulfamethylisoxazole; Simsinomin; Radonil; Sinomin; 4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamide; Sulphamethoxazol; Sulpha-methoxizole; Sulfamethalazole; Azo-gantanol; Sulphamethylisoxazole; Urobak; Sulfamethoxizole; 3-Sulfanilamido-5-methylisoxazole; Gantanol-DS; 4-amino-N-(5-methylisoxazol-3-yl)benzenesulfonamide; Gamazole; Sulphisomezole; Ro 4-2130; 4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide; 5-Methyl-3-sulfanilamidoisoxazole; MS 53; 3-Sulphanilamido-5-methylisoxazole; Benzenesulfonamide, 4-amino-N-(5-methyl-3-isoxazolyl)-; 5-Methyl-3-sulphanil-amidoisoxazole; 3-(p-Aminophenylsulfonamido)-5-methylisoxazole; 5-Methyl-3-sulfanylamidoisoxazole; N'-(5-Methyl-3-isoxazolyl)sulfanilamide; N1-(5-Methyl-3-isoxazolyl)sulfanilamide; N'-(5-Methylisoxazol-3-yl)sulphanilamide; Solfametossazolo [DCIT]; 3-(para-Aminophenylsulphonamido)-5-methylisoxazole; Sulfametoxazol [INN-Spanish]; Sulfamethoxazolum [INN-Latin]; Sulmeprim; Trimeth/Sulfa; A047; UNII-JE42381TNV; CCRIS 567; N(sup 1)-(5-Methyl-3-isoxazolyl)sulphanilamide; CHEBI:9332; N'-(5-Methyl-3-isoxazole)sulfanilamide; SMX; HSDB 3186; Ro 6-2580/11; 4-Amino-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide; Sulfanilamide, N'-(5-methyl-3-isoxazolyl)-; Sulfanilamide, N1-(5-methyl-3-isoxazolyl)-; EINECS 211-963-3; CHEMBL443; NSC 147832; BRN 0226453; MLS000069732; JE42381TNV; 4-AMINO-N-(5-METHYL-3-ISOXAZOYL)BENZENESULFONAMIDE; Sulfametoxazol; 4-amino-N-(5-methyl-1,2-oxazol-3-yl)benzene-1-sulfonamide; C10H11N3O3S; Solfametossazolo; N(sup1)-(5-Methyl-3-isoxazolyl)sulfanilamide; 5-Methyl-3-sulfonylamidoisoxazole; JLKIGFTWXXRPMT-UHFFFAOYSA-N; N(sup 1)-(5-Methyl-3-isoxazolyl)sulfanilamide; Sulfanilamide, N(1)-(5-methyl-3-isoxazolyl)-; Sulfamethoxazolum; MFCD00010546; NSC147832; NSC-147832; NCGC00016533-05; NCGC00186654-01; CAS-723-46-6; SMR000058223; DSSTox_CID_6064; 3-(p-Aminobenzenesulfonamido)-5-methylisoxazole; DSSTox_RID_78001; DSSTox_GSID_26064; 129378-89-8; [(4-aminophenyl)sulfonyl](5-methylisoxazol-3-yl)amine; 4-Amino-N-(5-methyl-3-isoxazolyl)-benzenesulfonamide; Sulfamethoxazole [USAN:INN:JAN]; SR-01000000217; Prestwick_453; ALBB-002089; Septran (Salt/Mix); Septrin (Salt/Mix); Sulfamethoxazole,(S); Eusaprim (Salt/Mix); Ro-4-2130; Spectrum_000994; Sulfamethoxazole(USAN); N1-(5-Methylisoxazol-3-yl)sulfanilamide; Opera_ID_882; 4563-84-2; Maybridge1_007190; Prestwick0_000177; Prestwick1_000177; Prestwick2_000177; Prestwick3_000177; Spectrum2_000788; Spectrum3_000584; Spectrum4_000345; Spectrum5_000982; Sulfamethoxazole [USAN:USP:INN:BAN:JAN]; Epitope ID:114999; Co-trimoxazole (Salt/Mix); SCHEMBL3656; Oprea1_114486; Oprea1_285680; BSPBio_000073; BSPBio_002028; KBioGR_000749; KBioSS_001474; KSC635S5T; MLS001055354; MLS001074165; MLS006011871; BIDD:GT0731; DivK1c_000649; SPECTRUM1500550; SPBio_000896; SPBio_001994; ARONIS018156; BPBio1_000081; DTXSID8026064; CTK5D5959; HMS502A11; HMS561O18; JLKIGFTWXXRPMT-UHFFFAOYSA-; KBio1_000649; KBio2_001474; KBio2_004042; KBio2_006610; KBio3_001528; KS-00004AEJ; ZINC89763; EBD3403; N1-(5-methylisoxazol-3-yl)-4-aminobenzene-1-sulfonamide; STX-608; WLN: T5NOJ C1 EMSWR DZ; NINDS_000649; HMS1568D15; HMS1921A21; HMS2092K03; HMS2095D15; HMS2233L13; HMS3259E06; HMS3372M22; HMS3655O22; HMS3712D15; Pharmakon1600-01500550; BCP02881; HY-B0322; KS-000000QU; Sulfamethoxazole (JP17/USP/INN); Sulfamethoxazole, analytical standard; Tox21_110480; Tox21_200353; ANW-43073; BBL004554; BDBM50029770; CCG-40166; HTS001394; KM1475; NSC757328; Ro-42130; s1915; SBB057675; SBB071655; STK007988; AKOS000200952; component of Azo Gantanol (Salt/Mix); Tox21_110480_1; BS-3542; CS-2363; DB01015; LS-1620; MCULE-1450176600; NC00537; NSC-757328; RTR-023663; TRA0076970; IDI1_000649; NCGC00016533-01; NCGC00016533-02; NCGC00016533-03; NCGC00016533-04; NCGC00016533-06; NCGC00016533-07; NCGC00016533-08; NCGC00016533-09; NCGC00016533-10; NCGC00016533-11; NCGC00016533-12; NCGC00016533-14; NCGC00021995-03; NCGC00021995-04; NCGC00021995-05; NCGC00257907-01; AC-11118; AK-36221; CPD000058223; H463; SAM002554930; SC-15160; ST024740; SY018888; BCP0726000283; N'-(5-Methyl-3-isoxazolyl)-Sulfanilamide; N1-(5-methyl-3-isoxazolyl)-Sulfanilamide; N1-(5-Methyl-3-isoxazolyl)sulphanilamide; SBI-0051524.P003; AB1009297; DB-055629; ST2418109; Sulfamethoxazole 100 microg/mL in Methanol; AB00052099; BB 0242379; FT-0602616; N^1-(5-Methyl-3-isoxazolyl)-Sulfanilamide; S0361; ST51006798; Sulfamethoxazole 1000 microg/mL in Methanol; SW196670-3; C07315; D00447; J10090; AB00052099-14; AB00052099-16; AB00052099_17; AB00052099_18; Ndimethyl1-(5-methyl-3-isoxazolyl)-Sulfanilamide; Q415843; Q-201762; SR-01000000217-2; SR-01000000217-3; Sulfamethoxazole, VETRANAL(TM), analytical standard; Sulfanilamide, N1-(5-methyl-3-isoxazolyl)- (8CI); 4-Amino-N-(5-methylisoxazol-3-yl)benzenesulphonamide; BRD-K28494619-001-05-0; BRD-K28494619-001-15-9; BRD-K28494619-001-26-6; Z57198677; 4-Amino-N-(5-methyl-isoxazol-3-yl)-benzene sulfonamide; 4-AMINO-N-[5-METHYL-3-ISOXAZOLYL]BENZENESULFONAMID; Sulfamethoxazole, British Pharmacopoeia (BP) Reference Standard; Sulfamethoxazole, certified reference material, TraceCERT(R); Sulfamethoxazole, European Pharmacopoeia (EP) Reference Standard; Sulfamethoxazole, United States Pharmacopeia (USP) Reference Standard; SULFAMETHOXAZOLE (8064-90-2 (TRIMETHOPRIM/SULFAMETHOXAZOLE); TMP/SMX (MIXTURE)); Sulfamethoxazole, Pharmaceutical Secondary Standard; Certified Reference Material; 08D; 4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamide; N1-(5-Methylisoxazol-3-yl)sulfanilamide; InChI=1/C10H11N3O3S/c1-7-6-10(12-16-7)13-17(14,15)9-4-2-8(11)3-5-9/h2-6H,11H2,1H3,(H,12,13); Sulfamethoxazole; A047
Sulphamethoxypyridazine 4-Amino-N-(6-methoxy-3-pyridazinyl)benzenesulfonamide; sulfamethoxypyridazine; 80-35-3; Sulphamethoxypyridazine; Sulfapyridazine; Sulfalex; Midicel; Sulfametoxipiridazine; Spofadazine; Sulfdurazin; Longin; 3-Sulfa-6-methoxypyridazine; Depovernil; Lederkyn; Lisulfen; Petrisul; Piridolo; Quinoseptyl; Retasulfin; Sulfametoxipiridazina; Sulfozona; Sultirene; Altezol; Davosin; Lentac; Medicel; Midikel; Myasul; Opinsul; Paramid; Retamid; Slosul; Vinces; Durox; Kinex; Kynex; Smop; Solfametossipiridazina; Paramid Supra; 3-Methoxy-6-sulfanylamidopyridazine; 3-Sulfanilamide-6-methoxypyridazine; 3-Sulfanilamido-6-methoxypyridazine; 6-Methoxy-3-sulfanilamidopyridazine; 6-Sulfanilamido-3-methoxypyridazine; Sulfamethoxypyridazinum; 4-amino-N-(6-methoxypyridazin-3-yl)benzenesulfonamide; Sulfamethoxipyridazinum; 3-(p-Aminobenzenesulfamido)-6-methoxypyridazine; 3-p-Aminobenzenesulphonamido-6-methoxypyridazine; sulfamethoxipyridazine; Benzenesulfonamide, 4-amino-N-(6-methoxy-3-pyridazinyl)-; CL 13494; 6-Methoxy-3-pyridazinylsulfanilamide; UNII-T034E4NS2Z; 4-Amino-N-(6-methoxy-3-pyridazinyl)-benzenesulfonamide; Solfametossipiridazina [DCIT]; RP 7522; 4-amino-N-(6-methoxy-3-pyridazinyl)benzenesulfonamide; CHEBI:102516; Sulfamethoxypyridazinum [INN-Latin]; Sulfametoxipiridazina [INN-Spanish]; EINECS 201-272-5; 3-(4-Aminobenzenesulfonamido)-6-methoxypyridazine; BRN 0277076; Sulfamethoxypyridazine [INN]; MLS000069641; T034E4NS2Z; N(1)-(6-Methoxy-3-pyridazinyl)sulfanilamide; N(sup 1)-(6-Methoxy-3-pyridazinyl)sulfanilamide; 4-Amino-N-(6-methoxy-3-pyridazinyl)benzolsulfonamid; NCGC00016324-01; N-(6-Methoxy-3-pyridazinyl)sulfanilamide; SMR000018386; DSSTox_CID_3611; DSSTox_RID_77108; DSSTox_GSID_23611; Sulfamethoxypyridazine (INN); W-104237; Sulfanilamide, N(sup 1)-(6-methoxy-3-pyridazinyl)-; CAS-80-35-3; SR-01000000179; Retasulphine; Kineks; N1-(6-Methoxy-3-pyridazinyl)sulfanilamide; Lederkyn (TN); Prestwick_118; PubChem8598; Sulfamethoxypyridazine [USP:INN:BAN]; Spectrum_001151; Opera_ID_698; Prestwick0_000724; Prestwick1_000724; Prestwick2_000724; Prestwick3_000724; Pyridazine, sulfamethoxy-; Spectrum2_001429; Spectrum3_001462; Spectrum4_000430; Spectrum5_001187; Epitope ID:122239; Sulphamethazine Sodium Salt; Oprea1_275757; SCHEMBL93617; BSPBio_000648; BSPBio_002983; KBioGR_000760; KBioSS_001631; 5-25-12-00424 (Beilstein Handbook Reference); MLS000100719; MLS001148433; DivK1c_000239; SPECTRUM1501156; SPBio_001538; SPBio_002587; BPBio1_000714; CHEMBL268869; 4-Amino-N-(6-methoxy-pyridazin-3-yl)-benzenesulfonamide; benzenesulfonamide,4-amino-n-(6-methoxy-3-pyridazinyl)-; DTXSID5023611; HMS500L21; KBio1_000239; KBio2_001631; KBio2_004199; KBio2_006767; KBio3_002483; ZINC49141; 4-amino-N-(6-methoxypyridazin-3-yl)benzene-1-sulfonamide; NINDS_000239; VLYWMPOKSSWJAL-UHFFFAOYSA-N; HMS1570A10; HMS1921L17; HMS2092J05; HMS2097A10; HMS2234F17; HMS3652H21; HMS3714A10; Pharmakon1600-01501156; 3-Methoxy-6-sulfanilamidopyridazine; HY-B1387; Tox21_110373; CCG-38976; NSC757875; s4250; AKOS000605846; Tox21_110373_1; API0004274; CS-4821; DB13773; MCULE-1902045342; NSC-757875; SDCCGMLS-0003277.P003; IDI1_000239; NCGC00016324-02; NCGC00016324-03; NCGC00016324-04; NCGC00016324-05; NCGC00016324-06; NCGC00016324-09; NCGC00022232-03; NCGC00022232-04; AC-12005; H467; SC-06824; ST007537; SBI-0051666.P002; Sulfamethoxypyridazine, analytical standard; LS-147808; AB00052228; FT-0653623; S0591; SW196429-3; D02439; Sulfanilamide, N1-(6-methoxy-3-pyridazinyl)-; AB00052228_12; Sulfamethoxypyridazine 100 microg/mL in Methanol; A839894; C-44344; Q7636177; SR-01000000179-3; SR-01000000179-4; Sulfamethoxypyridazine 100 microg/mL in Acetonitrile; BRD-K00938507-001-05-3; BRD-K00938507-001-13-7; [(4-aminophenyl)sulfonyl](6-methoxypyridazin-3-yl)amine; 4-azanyl-N-(6-methoxypyridazin-3-yl)benzenesulfonamide; F0391-0002; 4-amino-N-[6-(methyloxy)pyridazin-3-yl]benzenesulfonamide; Sulfamethoxypyridazine, VETRANAL(TM), analytical standard; 4-Amino-N-(6-methoxy-3-pyridazinyl)-benzenesulfonamide (9CI); Sulfamethoxypyridazine, European Pharmacopoeia (EP) Reference Standard; Sulfamethoxypyridazine; 5-25-12-00424 (Beilstein Handbook Reference)
Sulphanilamide 4-Aminobenzenesulfonamide; sulfanilamide; 4-Aminobenzenesulfonamide; 63-74-1; Sulphanilamide; Sulfamine; Sulphonamide; Sulfonylamide; p-Aminobenzenesulfonamide; Prontosil Album; Bacteramid; Streptasol; p-Sulfamoylaniline; Sulfonamide P; p-Aminobenzenesulfamide; Benzenesulfonamide, 4-amino-; Estreptocida; Exoseptoplix; Streptoclase; p-Sulfamidoaniline; Sulfamidyl; Sulfanalone; Sulfanidyl; Sulfanil; Sulfocidine; Sulfana; Sulfanilimidic acid; p-Anilinesulfonamide; p-Aminophenylsulfonamide; Ambeside; Antistrept; Astreptine; Astrocid; Bactesid; Collomide; Colsulanyde; Copticide; Deseptyl; Ergaseptine; Erysipan; Gombardol; Lysococcine; Neococcyl; Orgaseptine; Prontalbin; Prontylin; Proseptal; Proseptine; Proseptol; Pysococcine; Septanilam; Septinal; Septolix; Septoplex; Septoplix; Strepamide; Strepsan; Streptagol; Streptamid; Streptamin; Streptocid; Streptocide; Streptocom; Strepton; Streptopan; Streptosil; Streptozol; Streptozone; Streptrocide; Sulfocidin; Therapol; 4-Sulfamoylaniline; Albexan; Albosal; Dipron; Gerison; Infepan; Sanamid; Stramid; Tolder; Lusil; Prontosil White; Pronzin Album; Septamide Album; Stopton Album; Streptocid album; Prontosil I; Rubiazol A; White streptocide; PABS; Streptocide White; 4-Aminobenzene-1-Sulfonamide; p-Aminobenzenesulfonylamide; 4-Aminophenylsulfonamide; Fourneau 1162; Streptocidum; Sulfanilamide Vaginal Cream; Aniline-p-sulfonic amide; Benzenesulfonamide, p-amino-; 4-azanylbenzenesulfonamide; 4-Amino-benzenesulfonamide; Streptocide (VAN); Solfanilamide [DCIT]; Caswell No. 809A; p-Aminobenzensulfonamide; HSDB 223; 1162 F; para-aminobenzenesulfonamide; A-349; Sulfanilamidum [INN-Latin]; MFCD00007939; Sulfanilamida [INN-Spanish]; C6H8N2O2S; CCRIS 764; F 1162; UNII-21240MF57M; CHEBI:45373; 4-aminobenzene sulfonic acid amide; NSC 7618; CHEMBL21; EINECS 200-563-4; p-amino benzene sulfonamide; EPA Pesticide Chemical Code 077902; BRN 0511852; AI3-00952; NSC7618; F-1162; FDDDEECHVMSUSB-UHFFFAOYSA-N; 21240MF57M; AVC; CAS-63-74-1; NCGC00016285-02; NCGC00016285-05; Sulfanilamida; Sulfanilamidum; Sulfanilamide, >=99%; DSSTox_CID_3622; DSSTox_RID_77115; DSSTox_GSID_23622; Solfanilamide; SMR000059035; SR-01000763435; Sulfanilamide [INN:DCF]; sulfanilamine; Sulfanimide; Sulfanilamide [INN:DCF:NF]; sulphanilic amide; 4-sulphanilamide; Sulfanimide,(S); Streptocid (TN); delta-Sulfanilamide; Prestwick_36; 4-sulfamoyl-aniline; sulfanilamide reagent; sulfanilamide-reagent; 4-sulphamoyl aniline; Sulfanilamide (INN); Sulfanilamide, 98%; Spectrum_000489; 4-aminobenzensulfonamide; WLN: ZSWR DZ; 4-(Aminosulfonyl)aniline; 4-aminobenzenesulphonamide; p-aminobenzene sulfonamide; Prestwick0_000729; Prestwick1_000729; Prestwick2_000729; Prestwick3_000729; Spectrum2_000846; Spectrum3_001406; Spectrum4_000398; Spectrum5_001081; 4-aminobenzene sulfonamide; 4-aminobenzene-sulfonamide; ACMC-1AYS4; p-aminosulfonyl phenylamine; SCHEMBL740; 4-amino-benzenesulphonamide; Epitope ID:122232; AVC (TN); Oprea1_273157; p-aminobenzene sulfonyl amide; BSPBio_000658; BSPBio_003052; KBioGR_000955; KBioSS_000969; 4-14-00-02658 (Beilstein Handbook Reference); KSC490E8T; MLS001074682; MLS002152940; BIDD:GT0170; DivK1c_000528; SPECTRUM1500646; SPBio_000831; SPBio_002597; aromatic sulfonamide compound 5; BPBio1_000724; halogenosulfanilamide deriv. 5a; ZINC2101; (4-(Aminosulfonyl)phenyl)amine; DTXSID4023622; SCHEMBL11880061; BDBM10857; CTK3J0289; HMS501K10; KBio1_000528; KBio2_000969; KBio2_003537; KBio2_006105; KBio3_002272; Sulfanilamide, p.a., 99.0%; NINDS_000528; HMS1570A20; HMS1921O07; HMS2092E20; HMS2097A20; HMS2233B19; HMS3370J16; HMS3655K19; HMS3714A20; HMS3744M13; Pharmakon1600-01500646; Ro13354; EBD35543; HY-B0242; KS-00000V0E; NSC-7618; Tox21_110351; Tox21_201331; Tox21_303336; ANW-43069; aromatic/heteroaromatic sulfonamide 2; BBL005257; c1264; CCG-40302; LS-274; NSC757404; s1685; SBB008928; STK298902; AKOS000119305; Tox21_110351_1; CS-2221; DB00259; MCULE-8746683155; NSC-757404; RTR-021919; IDI1_000528; NCGC00016285-01; NCGC00016285-03; NCGC00016285-04; NCGC00016285-06; NCGC00016285-08; NCGC00091144-01; NCGC00091144-02; NCGC00091144-03; NCGC00257174-01; NCGC00258883-01; Sulfanilamide 100 microg/mL in Methanol; AK-77666; AS-13239; BP-12552; H701; SC-16246; ST079295; Sulfanilamide (4-Aminobenzenesulfonamide); SY009959; SBI-0051575.P002; 4-Aminobenzenesulphonamide (Sulphanilamide); AB1002011; ST2411104; TR-021919; AB00052138; FT-0657032; S0119; S0381; S0833; SW196353-3; Sulfanilamide, JIS special grade, >=99.7%; Sulfanilamide, Vetec(TM) reagent grade, 97%; C07458; D08543; M-3994; 36799-EP2272517A1; 36799-EP2272834A1; 36799-EP2289871A1; 36799-EP2301923A1; 36799-EP2301929A1; 36799-EP2301935A1; 36799-EP2305250A1; 36799-EP2305640A2; 36799-EP2305674A1; 36799-EP2305808A1; 36799-EP2311796A1; 36799-EP2311797A1; 36799-EP2311798A1; 36799-EP2311799A1; 36799-EP2311801A1; 91143-EP2295053A1; 91143-EP2305219A1; AB00052138-10; AB00052138_11; AB00052138_12; A834498; AC-907/25014139; Q423423; Sulfanilamide, VETRANAL(TM), analytical standard; SR-01000763435-2; SR-01000763435-3; SR-01000763435-4; F2190-0451; BENZENESULFONIC ACID,4-AMINO,AMIDE SULFANILAMIDE; Sulfanilamide, European Pharmacopoeia (EP) Reference Standard; Sulfanilamide, puriss. p.a., >=99% (calc. to the dried substance); Sulfanilamide, United States Pharmacopeia (USP) Reference Standard; InChI=1/C6H8N2O2S/c7-5-1-3-6(4-2-5)11(8,9)10/h1-4H,7H2,(H2,8,9,10; Sulfanilamide Melting Point Standard, United States Pharmacopeia (USP) Reference Standard; Sulfanilamide melting point standard, Pharmaceutical Secondary Standard; Certified Reference Material; Sulfanilamide; A-349
Sulphapyridine 4-Amino-N-2-pyridinylbenzenesulfonamide; sulfapyridine; 144-83-2; Sulphapyridine; 2-Sulfapyridine; Sulfidin; 2-Sulfanilamidopyridine; Sulfidine; 2-Sulfanilylaminopyridine; Streptosilpyridine; Coccoclase; Eubasinum; Piridazol; Pyridazol; Eubasin; Haptocil; Plurazol; Relbapiridina; Pyriamid; Septipulmon; Thioseptal; Adiplon; Dagenan; Trianon; Ronin; 2-Sulfanilamidopyridin; N-2-Pyridylsulfanilamide; Solfapiridina; Sulfapiridina; Sulfapyridinum; N1-2-Pyridylsulfanilamide; 4-amino-N-pyridin-2-ylbenzenesulfonamide; 2-(p-Aminobenzenesulphonamido)pyridine; Benzenesulfonamide, 4-amino-N-2-pyridinyl-; 4-amino-N-pyridin-2-yl-benzenesulfonamide; N(sup 1)-2-Pyridylsulfanilamide; 2-Sulfanilyl aminopyridine; 4-(2-Pyridinylsulfonyl)aniline; 4-[(2-Pyridylamino)sulfonyl]aniline; 2-(4-Aminobenzenesulfonamido)pyridine; 4-amino-N-(pyridin-2-yl)benzenesulfonamide; Solfapiridina [DCIT]; N(sup1)-Pyridylsulfanilamide; M+B 693; N(1)-Pyridylsulfanilamide; Sulfapyridinum [INN-Latin]; Sulfapiridina [INN-Spanish]; N(1)-2-Pyridylsulfanilamide; A-499; 2-Sulfanilamidopyridin [German]; 4-Amino-N,2-pyridinylbenzenesulfonamide; M + B 693; UNII-Y5V2N1KE8U; NSC 4753; NSC 41791; Sulfanilamide, N(sup 1)-2-pyridyl-; M&B 693; Sulfanilamide, N1-2-pyridyl-; C11H11N3O2S; CHEBI:132842; EINECS 205-642-7; 4-amino-N-(pyridin-2-yl)benzene-1-sulfonamide; Y5V2N1KE8U; 4-amino-n-(2-pyridinyl)benzenesulfonamide; AI3-01049; MLS000069725; NSC4753; GECHUMIMRBOMGK-UHFFFAOYSA-N; Sulfapyridine, 95%; NCGC00016408-01; Sulphapyridin; CAS-144-83-2; SMR000058213; DSSTox_CID_6067; DSSTox_RID_78003; DSSTox_GSID_26067; WLN: T6NJ BMSWR DZ; 4-amino-N-(2-pyridyl)benzenesulfonamide; M and B 693; [(4-aminophenyl)sulfonyl]-2-pyridylamine; Sulfapyridine (TN); 4-Amino-n-2-pyridinyl-benzenesulfonamide; Sulfapyridine [USAN:INN:BAN]; SR-01000000207; N'-2-Pyridylsulfanilide; Sulfapyridine (USP/INN); Sulfapyridine [USP:INN:BAN]; sulfapyridine III; 4-AMINO-N-2-PYRIDINYLBENZENESULFONAMIDE; SFY; ALBB-006215; Prestwick_1015; Spectrum_000996; Sulfapyridine (Dagenan); Prestwick0_000762; Prestwick1_000762; Prestwick2_000762; Prestwick3_000762; Spectrum2_001323; Spectrum3_001773; Spectrum4_000346; Spectrum5_001182; CHEMBL700; Epitope ID:122235; EC 205-642-7; cid_5336; Sulfapyridine, >=99.0%; Oprea1_344996; SCHEMBL44219; BSPBio_000804; BSPBio_003265; KBioGR_000751; KBioSS_001476; AO-801/41077453; DivK1c_000216; SPECTRUM1500551; SPBio_001445; SPBio_002743; BPBio1_000886; ZINC2105; DTXSID3026067; BDBM39340; CTK3J2133; GECHUMIMRBOMGK-UHFFFAOYSA-; HMS500K18; KBio1_000216; KBio2_001476; KBio2_004044; KBio2_006612; KBio3_002766; NINDS_000216; 4-(2-Pyridinylsulfonyl)aniline #; HMS1570I06; HMS1921C03; HMS2092K05; HMS2097I06; HMS2233H20; HMS3372N13; HMS3714I06; Pharmakon1600-01500551; HY-B0212; NSC-4753; NSC41791; Tox21_110426; ANW-43071; BBL007713; CCG-39261; LS-854; NSC-41791; NSC757329; s1617; SBB003154; STK292439; 2-(p-Aminobenzenesulfonamido)pyridine; AKOS000121424; Tox21_110426_1; CS-2157; DB00891; HS-0063; M&B-693; MCULE-7911106459; NSC-757329; RTR-005667; Sulfanilamide, N1-2-pyridyl- (8CI); VZ28286; IDI1_000216; KS-00000G93; UPCMLD0ENAT5889155:001; NCGC00016408-02; NCGC00016408-03; NCGC00016408-04; NCGC00016408-05; NCGC00016408-06; NCGC00016408-09; NCGC00016408-10; NCGC00022008-03; NCGC00022008-04; Sulfanilamide, N1-2(1H)-pyridylidene-; Sulfapyridine 100 microg/mL in Methanol; AC-26818; AK400564; H460; SC-65296; SBI-0051525.P003; 4-azanyl-N-pyridin-2-yl-benzenesulfonamide; AB2000164; DB-042750; TR-005667; AB00052100; BB 0258406; Coccoclase; Eubasin; Eubasinum; Haptocil; Dagenan; FT-0631839; R1664; S0071; ST45026614; Benzenesulfonamide, 4-amino-N-(2-pyridinyl)-; D02434; J10161; AB00052100_14; AB00052100_15; A808279; Sulfapyridine, VETRANAL(TM), analytical standard; Q3976827; SR-01000000207-2; SR-01000000207-3; W-108148; BRD-K41406082-001-05-5; BRD-K41406082-001-09-7; Z271004858; 4-amino-N-(1,2-dihydropyridin-2-ylidene)benzenesulfonamide; Sulfapyridine, European Pharmacopoeia (EP) Reference Standard; 4-Amino-N-(pyrimidin-2-yl) benzenesulfonamide (Sulfadiazine) (14); Sulfapyridine, United States Pharmacopeia (USP) Reference Standard; Sulfapyridine Melting Point Standard, United States Pharmacopeia (USP) Reference Standard; InChI=1/C11H11N3O2S/c12-9-4-6-10(7-5-9)17(15,16)14-11-3-1-2-8-13-11/h1-8H,12H2,(H,13,14); Sulfapyridine melting point standard, Pharmaceutical Secondary Standard; Certified Reference Material; Sulfapyridine; A-499
Sulphasalazine 2-Hydroxy-5-[2-[4-[(2-pyridinylamino)sulfonyl]phenyl]diazenyl]benzoic acid; Sulfasalazine; S.A.S.-500
Sulphathiazole 4-Amino-N-2-thiazolybenzenesulfonamide; Sulfathiazole; M+B 760
Sulphisoxazole sulfisoxazole; Sulfafurazole; 127-69-5; Sulphafurazole; Sulfisoxazol; Sulfafurazol; Sulfaisoxazole; Sulfofurazole; Sulfisoxasole; Sulphaisoxazole; Sulfadimethylisoxazole; Gantrisin; Alphazole; Amidoxal; Sulfalar; Sulfoxol; Sulfisoxazole dialamine; Sulphafurazolum; Renosulfan; Sulfasoxazole; Sulfisonazole; Accuzole; Soxomide; Sulfazin; Sulfizin; Sulsoxin; Sosol; Roxosul tablets; Sulphafurazol; Sulphisoxazol; Sulphofurazole; Chemouag; Cosoxazole; Gantrisona; Gantrosan; Isoxamin; Neazolin; Neoxazol; Sulfagan; Sulfasol; Uritrisin; Entusil; Entusul; Pancid; Soxisol; Stansin; Sulbio; Thiasin; Unisulf; Sulphadimethylisoxazole; Norilgan-S; Tl-azole; V-Sul; SK-Soxazole; Sulfafurazolum; Dorsulfan; Gantrisine; Novazolo; Novosaxazole; Saxosozine; Sodizole; Soxamide; Soxazole; Soxitabs; Sulfapolar; Sulfisin; Sulfizol; Sulfizole; Urisoxin; Roxosul; Urogan; Vagilia; Azo Gantrisin; Dorsulfan warthausen; Koro-sulf; SOXO; Sulfisoxazolum; Sulphisoxazole; 4-amino-N-(3,4-dimethylisoxazol-5-yl)benzenesulfonamide; J-Sul; 3,4-Dimethyl-5-sulfonamidoisoxazole; 3,4-Dimethyl-5-sulfanilamidoisoxazole; 5-Sulfanilamido-3,4-dimethylisoxazole; Benzenesulfonamide, 4-amino-N-(3,4-dimethyl-5-isoxazolyl)-; 4-Amino-N-(3,4-dimethyl-5-isoxazolyl)benzenesulfonamide; 3,4-Dimethyl-5-sulphonamidoisoxazole; 3,4-Dimethylisoxazole-5-sulfanilamide; G-sox; 3,4-Dimethyl-5-sulphanilamidoisoxazole; 3,4-Dimethylisoxazole-5-sulphanilamide; Sulfazin (VAN); 5-Sulphanilamido-3,4-dimethyl-isoxazole; Solfafurazolo [DCIT]; 5-(4-Aminophenylsulfonamido)-3,4-dimethylisoxazole; 5-(p-Aminobenzenesulfonamido)-3,4-dimethylisoxazole; 5-(p-Aminobenzenesulphonamido)-3,4-dimethylisoxazole; N1-(3,4-Dimethyl-5-isoxazolyl)sulfanilamide; N'-(3,4)Dimethylisoxazol-5-yl-sulphanilamide; NCI-C50022; Sulfafurazolum [INN-Latin]; ERYZOLE; NU 445; Pediazole; U.S.-67; 4-Amino-N-(3,4-dimethyl-5-isoxazolyl)benzenesulphonamide; CCRIS 568; HSDB 797; Sulfafurazole (INN); N(Sup1)-(3,4-Dimethyl-5-isoxazolyl)sulfanilamide; UNII-740T4C525W; C11H13N3O3S; CHEBI:102484; Gantrisin (TN); component of Azo-Sulfizin; EINECS 204-858-9; 4-amino-N-(3,4-dimethyl-1,2-oxazol-5-yl)benzenesulfonamide; NSC 13120; component of Azo Gantrisin; CHEMBL453; NSC 683536; BRN 0263871; N(sup 1)-(3,4-Dimethyl-5-isoxazolyl)sulphanilamide; AI3-24003; NHUHCSRWZMLRLA-UHFFFAOYSA-N; NSC13120; 3,4-Dimethylisoxale-5-sulfanilamide; N(sup 1)-(3,4-Dimethyl-5-isoxazolyl)sulfanilamide; NSC-13120; NSC683536; Sulfafurazole [INN]; 740T4C525W; NSC-683536; Sulfisoxazole, 99%; NCGC00016384-03; NCGC00016384-10; Azosulfizin; Solfafurazolo; Sulfasoxizole; Sulphafuraz; 4-Amino-N-(3,4-dimethyl-isoxazol-5-yl)-benzenesulfonamide; Astrazolo; Bactesulf; Barazae; CAS-127-69-5; Neoxazoi; Resoxol; Roxoxol; Sulfagen; Suloxsol; Ganda; DSSTox_CID_1292; N(1)-(3,4-dimethyl-5-isoxazolyl)sulfanilamide; DSSTox_RID_76064; DSSTox_GSID_21292; N(1)-(3,4-dimethyl-5-isoxazolyl)sulphanilamide; Sulfanilamide, N1-(3,4-dimethyl-5-isoxazolyl)-; 5-(p-Aminobenzenesulfonamido)-3,4-dimethylisooxale; Sulfanilamide, N(sup 1)-(3,4-dimethyl-5-isoxazolyl)-; [(4-aminophenyl)sulfonyl](3,4-dimethylisoxazol-5-yl)amine; Sulfisoxazole [USAN]; Sulfafuraz ole; WLN: T5NOJ CMSWR DZ& D1 E1; Sulfanilamide,4-dimethyl-5-isoxazolyl)-; 1021066-10-3; SMR000037657; 5-Sulfanilamido-3,4-dimethyl-isoxazole; Benzenesulfonamide,4-dimethyl-5-isoxazolyl)-; N1-(3,4-dimethylisoxazole-5-yl)sulfanilamide; SR-01000003085; Sulfisoxazole [USP:JAN]; Gantrizin; US-67; Component of Azo Gantrisin Accuzole; Prestwick_726; Sulfisoxazole - Carc; 3,4-dimethylisoaxazole-5-sulfanilimide; Spectrum_001024; Tocris-0731; Prestwick0_000334; Prestwick1_000334; Prestwick2_000334; Prestwick3_000334; Spectrum2_001325; Spectrum3_001728; Spectrum4_000349; Spectrum5_001222; Azo-Sulfizin (Salt/Mix); Azo Gantrisin (Salt/Mix); Epitope ID:122240; Sulfisoxazole (JP17/USP); Sulfisoxazole, >=99.0%; Oprea1_680668; Oprea1_828173; SCHEMBL23467; BSPBio_000367; BSPBio_003376; KBioGR_000757; KBioSS_001504; 4-27-00-04747 (Beilstein Handbook Reference); MLS000028495; MLS000037737; MLS000563718; BIDD:GT0322; DivK1c_000579; SPECTRUM1500555; SPBio_001449; SPBio_002288; BPBio1_000405; DTXSID6021292; CTK7D7932; HMS501M21; KBio1_000579; KBio2_001504; KBio2_004072; KBio2_006640; KBio3_002596; Sulfafurazole; Gantrisin Pediatric; NINDS_000579; HMS1569C09; HMS2092K13; HMS2096C09; HMS2233G23; HMS3259C06; HMS3266N17; HMS3374K11; HMS3411F03; HMS3655B03; HMS3675F03; HMS3713C09; Pharmakon1600-01500555; ALBB-014131; HY-B0323; NSC33807; NSC38588; STR04988; ZX-AH011786; Tox21_110409; Tox21_112958; Tox21_202265; Tox21_302851; BDBM50034452; CCG-39263; LS-713; MFCD00003150; NSC-33807; NSC-38588; NSC757343; s1916; SBB007602; STK400452; ZINC96006009; AKOS000119074; AKOS000310021; Tox21_110409_1; AC-1941; CS-2364; DB00263; MCULE-3522661051; NC00536; NSC-757343; ABA-9370315; IDI1_000579; NCGC00016384-01; NCGC00016384-02; NCGC00016384-04; NCGC00016384-05; NCGC00016384-06; NCGC00016384-07; NCGC00016384-08; NCGC00016384-09; NCGC00016384-11; NCGC00016384-12; NCGC00016384-14; NCGC00016384-15; NCGC00023116-02; NCGC00023116-05; NCGC00023116-06; NCGC00023116-07; NCGC00023116-08; NCGC00256605-01; NCGC00259814-01; Sulfisoxazole 100 microg/mL in Methanol; AK114529; CPD000037657; R536; SAM002554929; SC-15955; ST059445; SBI-0051529.P003; AB2000373; DB-041869; UPCMLD00X127-69-5:001; AB00052104; BB 0259593; FT-0631743; SW196872-3; U0098; C07318; D00450; J10241; N1-(3,4-Dimethyl-5-isoxazolyl)sulphanilamide; Y-9398; AB00052104-14; AB00052104_15; AB00052104_16; Q372598; Sulfisoxazole, VETRANAL(TM), analytical standard; 5-(4-Aminophenylsulphonamido)-3,4-dimethylisoxazole; J-005528; SR-01000003085-2; SR-01000003085-5; SR-01000003085-6; 5-(4-aminop henylsulfonamido)-3,4-dimethylisoxazole; 5-(p-Aminobenzenesulphonamide)-3,4-dimethylisoxazole; BRD-K50859149-001-05-4; BRD-K50859149-001-10-4; N(sup 1)-(3,4-dimethyl-5-isoxazolyl)-sulfanilamide; Sulfanilamide, N(sup1)-(3,4-dimethyl-5-isoxazolyl)-; Sulfanilamide, N.sup1.-(3,4-dimethyl-5-isoxazolyl)-; F0848-0391; 4-amino-N-(3,4-dimethyl-5-isoxazolyl)benzene-sulfonamide; 4-Amino-N-(3,4-dimethyl-5-isoxazolyl)benzenesulfonamide #; 4-amino-N-(3,4-dimethylisoxazol-5-yl)-benzenesulfonamide; 4-amino-N-(dimethyl-1,2-oxazol-5-yl)benzene-1-sulfonamide; Sulfafurazole, European Pharmacopoeia (EP) Reference Standard; 4-amino-N-(3,4-dimethyl-1,2-oxazol-5-yl)benzene-1-sulfonamide; Sulfisoxazole, United States Pharmacopeia (USP) Reference Standard; InChI=1/C11H13N3O3S/c1-7-8(2)13-17-11(7)14-18(15,16)10-5-3-9(12)4-6-10/h3-6,14H,12H2,1-2H; U.S.-67
Sulpiride 5-(Aminosulfonyl)-N-[(1-Ethyl-2-pyrrolidinyl)methyl]-2-methoxybenzamide; Sulpiride; R.D. 1403
Suprofen alpha-Methyl-4-(2-thienylcarbonyl)benzeneacetic acid; Suprofen; R 25061
Swainsonine (1S,2R,8R,8aR)-Octahydro-1,2,8-indolizinetriol; swainsonine; Tridolgosir; 72741-87-8; (-)-Swainsonine; Tridolgosir [INN]; UNII-RSY4RK37KQ; RSY4RK37KQ; 1S-8AB-OCTAHYDRO-INDOLIZIDINE-1A,2A,8B-TRIOL; CHEBI:9367; CHEMBL371197; FXUAIOOAOAVCGD-WCTZXXKLSA-N; (1S,2R,8R,8aR)-Octahydro-1,2,8-indolizinetriol; (1S,2R,8R,8aR)-octahydroindolizine-1,2,8-triol; NCGC00163481-02; 1,2,8-Indolizinetriol, octahydro-, (1S-(1alpha,2alpha,8beta,8abeta))-; SWA; Swainosine; Locoweed deriv.; NSC614553; 1hww; Octahydro-1,2,8-indolizinetriol hydrochloride; (1S,2R,8R,8aR)-1,2,3,5,6,7,8,8a-octahydroindolizine-1,2,8-triol; DSSTox_CID_26356; DSSTox_RID_81558; CBiol_001919; DSSTox_GSID_46356; BSPBio_001148; KBioGR_000488; KBioSS_000488; CHEMBL63139; SCHEMBL765848; (-)-(1S,2R,8R,8aR)-1,2,8-Trihydroxyoctahydroindolizine Hydrochloride; DTXSID5046356; KBio2_000488; KBio2_003056; KBio2_005624; KBio3_000895; KBio3_000896; Bio1_000205; Bio1_000694; Bio1_001183; Bio2_000414; Bio2_000894; HMS1362J09; HMS1792J09; HMS1990J09; HMS3403J09; Octahydro-indolizine-1,2,8-triol; HY-N6722; ZINC3875041; Tox21_112058; 2057AH; BDBM50016706; BDBM50168995; MFCD00017554; (1S,2R,8aR)-Octahydroindolizinetriol; AKOS016344385; CCG-208274; DB02034; NSC-614553; IDI1_002169; SMP1_000286; NCGC00163481-03; NCGC00163481-04; LS-83623; CAS-72741-87-8; B7316; BB 0261154; CS-0015643; FT-0630815; C10173; (1S, 2R, 8R, 8AR)-1,2,8-Indolizidinetriol; Q415324; SR-05000002325; (1S,2R,8R,8aR)-1,2,8-Octahydroindolizidinetriol; SR-05000002325-2; (1S,2R,8R,8aR)-Octahydro-indolizine-1,2,8-triol; 1,8-Indolizinetriol, octahydro-, (1S,2R,8R,8aR)-; CFCE4066-9132-492F-B4E1-B50B974FE148; 1,2,8-Indolizinetriol, octahydro-, (1S-(1-alpha,2-alpha,8-beta,8a-beta))-; 1,8-Indolizinetriol, octahydro-,[1S-(1.alpha.,2.alpha., 8.beta.,8a.beta.)]-; SWS; Swainsonine; Swainsonine
TOLAZAMIDE tolazamide; Tolinase; 1156-19-0; Norglycin; Tolanase; Diabewas; Tolazolamide; Tolazamida; Tolazamidum; 1-(Hexahydro-1-azepinyl)-3-p-tolylsulfonylurea; N-(p-Toluenesulfonyl)-N'-hexamethyleniminourea; U-17835; 4-(p-Tolylsulfonyl)-1,1-hexamethylenesemicarbazide; NCI-C03327; 1-(Hexahydro-1H-azepin-1-yl)-3-(p-tolylsulfonyl)urea; Tolazamidum [INN-Latin]; Tolazamida [INN-Spanish]; U 17835; CCRIS 591; NSC-70762; UNII-9LT1BRO48Q; Urea, 1-(hexahydroazepin-1-yl)-3-p-tolylsulfonyl-; EINECS 214-588-3; Urea, 1-(hexahydro-1H-azepin-1-yl)-3-(p-tolylsulfonyl)-; BRN 1323565; HSDB 3192; NSC 70762; 1-(azepan-1-yl)-3-(4-methylphenyl)sulfonylurea; 9LT1BRO48Q; Benzenesulfonamide, N-[[(hexahydro-1H-azepin-1-yl)amino]carbonyl]-4-methyl-; AI3-50826; MLS000028534; CHEBI:9613; N-[(azepan-1-ylamino)carbonyl]-4-methylbenzenesulfonamide; C14H21N3O3S; N-(((Hexahydro-1H-azepin-1-yl)-amino)carbonyl)-4-methylbenzenesulfonamide; NSC70762; N-(azepan-1-ylcarbamoyl)-4-methylbenzenesulfonamide; Benzenesulfonamide, N-(((hexahydro-1H-azepin-1-yl)amino)carbonyl)-4-methyl-; 1-(Hexahydro-1H-azepin-1-yl)-3-(p-toluenesulfonyl)urea; NCGC00016009-10; SMR000058290; CAS-1156-19-0; DSSTox_CID_1358; Benzenesulfonamide, N-(((hexahydro-1H-azepin-1-yl)-amino)carbonyl)-4-methyl-; DSSTox_RID_76105; DSSTox_GSID_21358; W-109110; 1-(((((4-Methylphenyl)sulfonyl)amino)carbonyl)amino)azepane; Tolamide; N-(((hexahydro-1H-azepin-1-yl)amino)carbonyl)-4-methylbenzenesulfonamide; N-[[(Hexahydro-1H-azepin-1-yl)amino]carbonyl]-4-methylbenzenesulfonamide; Tolinase (TN); Tolazamide [USAN:INN:BAN:JAN]; SR-01000003105; 1-[(Azepan-1-ylamino)carbonyl]-4-methylbenzenesulfonamide; 1-[({[(4-methylphenyl)sulfonyl]amino}carbonyl)amino]azepane; Ronase; (azaperhydroepinylamino)-N-[(4-methylphenyl)sulfonyl]carboxamide; N-{[(hexahydro-1H-azepin-1-yl)-amino]carbonyl}-4-methylbenzenesulfonamide; Prestwick_865; Tolazamide [USAN:USP:INN:BAN:JAN]; Spectrum_001269; Opera_ID_1740; Prestwick0_000554; Prestwick1_000554; Prestwick2_000554; Prestwick3_000554; Spectrum2_001449; Spectrum3_001473; Spectrum4_000240; Spectrum5_001204; Lopac-T-2408; CHEMBL817; T 2408; 3-azepan-1-yl-1-(4-methylphenyl)sulfonyl-urea; NCIOpen2_008361; CBiol_001918; Lopac0_001195; Oprea1_061180; SCHEMBL34417; BSPBio_000627; BSPBio_001505; BSPBio_003025; KBioGR_000225; KBioGR_000939; KBioSS_000225; KBioSS_001749; Tolazamide (JAN/USP/INN); 1-(azepan-1-yl)-3-(4-methylbenzenesulfonyl)urea; 5-20-04-00062 (Beilstein Handbook Reference); MLS001076161; DivK1c_000212; SPECTRUM1501201; SPBio_001317; SPBio_002548; BPBio1_000691; GTPL6847; WLN: T7NTJ AMVMSWR D1; DTXSID3021358; BCBcMAP01_000061; HMS500K14; KBio1_000212; KBio2_000225; KBio2_001749; KBio2_002793; KBio2_004317; KBio2_005361; KBio2_006885; KBio3_000449; KBio3_000450; KBio3_002525; Tolazamide pound>>NSC 70762; ZINC57512; NINDS_000212; OUDSBRTVNLOZBN-UHFFFAOYSA-N; Bio1_000204; Bio1_000693; Bio1_001182; Bio2_000225; Bio2_000705; HMS1361L07; HMS1569P09; HMS1791L07; HMS1921P19; HMS1989L07; HMS2089L10; HMS2092L09; HMS2096P09; HMS2232L21; HMS3259O18; HMS3263P11; HMS3369L04; HMS3402L07; HMS3713P09; Pharmakon1600-01501201; BCP23550; HY-B0920; Tox21_110281; Tox21_201507; Tox21_300416; Tox21_501195; 2761AH; CCG-39178; GP6227; LS-578; MFCD00083504; NSC758149; SBB058190; AKOS015913823; Tox21_110281_1; ACN-053046; API0004439; DB00839; KS-1438; LP01195; MCULE-9265102499; NC00590; NSC-758149; SDCCGSBI-0051162.P004; Benzenesulfonamide, {N-[[(hexahydro-1H-azepin-1-yl)amino]carbonyl]-4-methyl-}; IDI1_000212; IDI1_033975; NCGC00016009-01; NCGC00016009-02; NCGC00016009-03; NCGC00016009-04; NCGC00016009-05; NCGC00016009-06; NCGC00016009-07; NCGC00016009-08; NCGC00016009-09; NCGC00016009-11; NCGC00016009-12; NCGC00016009-13; NCGC00016009-14; NCGC00016009-15; NCGC00016009-16; NCGC00016009-17; NCGC00016009-19; NCGC00023701-03; NCGC00023701-04; NCGC00023701-05; NCGC00023701-06; NCGC00023701-07; NCGC00023701-08; NCGC00023701-09; NCGC00023701-10; NCGC00254501-01; NCGC00259058-01; NCGC00261880-01; AK546472; CPD000058290; SAM002564236; 1-(azepan-1-yl)-3-(p-tolylsulfonyl)urea; SBI-0051162.P003; AB00052247; EU-0101195; FT-0675268; ST51015133; SW196991-3; D00379; AB00052247-15; AB00052247_16; AB00052247_17; C-55259; 1-(azepan-1-yl)-3-[(4-methylbenzene)sulfonyl]urea; Q7814101; SR-01000003105-2; SR-01000003105-4; SR-01000003105-5; SR-01000003105-8; BRD-K32164935-001-06-8; BRD-K32164935-001-17-5; BRD-K32164935-001-28-2; F2173-1137; 1-[(([(4-Methylphenyl)sulfonyl]amino)carbonyl)amino]azepane #; Tolazamide, United States Pharmacopeia (USP) Reference Standard; Benzenesulfonamide, N-[[(hexahydro-1-azepinyl)amino]carbonyl]-4-methyl-; Tolazamide; U 17835
Tamoxifen (Z)-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy-N,N-dimethylethanamine; Ethanamine, 2-(4-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethyl-, (Z)-; CCRIS 3275
Taurine taurine; 2-aminoethanesulfonic acid; 107-35-7; L-Taurine; tauphon; Ethanesulfonic acid, 2-amino-; 2-Aminoethylsulfonic acid; O-Due; 2-Sulfoethylamine; taufon; Aminoethanesulfonic acid; aminoethylsulfonic acid; beta-Aminoethylsulfonic acid; 2-aminoethane-1-sulfonic acid; Taurinum [Latin]; Taurina [Spanish]; FEMA No. 3813; Taurine [INN]; CCRIS 4721; UNII-1EQV5MLY3D; NCI-C60606; AI3-18307; NSC32428; EINECS 203-483-8; NSC 32428; 1EQV5MLY3D; 2-aminoethane sulfonic acid; .beta.-Aminoethylsulfonic acid; 1-Aminoethane-2-sulfonic acid; CHEBI:15891; XOAAWQZATWQOTB-UHFFFAOYSA-N; MFCD00008197; NSC-32428; Taurine, 99%; NCGC00015997-06; DSSTox_CID_1304; DSSTox_RID_76069; DSSTox_GSID_21304; Taurine Hydrochloride; 2-amino-ethanesulfonic acid; Taurina; Taurinum; CAS-107-35-7; SMR000326743; SR-01000076144; Taurine [USP:INN:BAN]; C2H7NO3S; Taurineold; Taukard; HSDB 8167; Aminoethylsulfonate; Taurine,(S); Taurine (TN); b-Aminoethylsulfonate; Taurine (8CI); 2-Aminoethylsulfonate; 2-aminoethyl sulfonate; beta-Aminoethylsulfonate; PubChem18250; Tocris-0209; 2aminoethanesulfonic acid; Taurine, >=99%; b-Aminoethylsulfonic acid; 2-AminoethanesulfonicAcid; Lopac-T-0625; WLN: Z2SWQ; 1-Aminoethane-2-sulfonate; ACMC-2098vs; bmse000120; bmse000805; bmse000863; EC 203-483-8; 2-aminoethanesulfonic acid.; Lopac0_001134; SCHEMBL23068; Taurine, >=98%, FG; KSC178O6B; MLS000859681; MLS001332383; MLS001332384; ARONIS27193; Taurine (JP17/USP/INN); Aminoethylsulfonic acid (JAN); CHEMBL239243; GTPL2379; DTXSID3021304; CTK0H8760; KS-00000ADB; Taurine, >=99.0% (T); HMS2093L13; HMS2233D19; HMS3263D09; HMS3370J18; Pharmakon1600-01505463; HY-B0351; KS-000048OD; RKL10149; ZINC3809490; Tox21_110277; Tox21_202520; Tox21_501134; ANW-15782; BDBM50357220; LS-439; NSC759150; s2008; STL197941; AKOS005208848; Tox21_110277_1; CCG-205208; CS-2397; DB01956; Ethanesulfonic acid, 2-amino- (9CI); LP01134; MCULE-6041857208; NE10562; NSC-759150; RTR-001805; SDCCGSBI-0051101.P003; Taurine, BioUltra, >=99.5% (T); Taurine, SAJ first grade, >=98.5%; TRA-0183757; 107-35-7, 2-Aminoethanesulfonic acid; NCGC00015997-01; NCGC00015997-02; NCGC00015997-03; NCGC00015997-04; NCGC00015997-05; NCGC00015997-07; NCGC00015997-08; NCGC00015997-10; NCGC00024497-01; NCGC00024497-02; NCGC00024497-03; NCGC00024497-04; NCGC00024497-05; NCGC00260069-01; NCGC00261819-01; AS-13587; I815; NCI60_002814; SC-19115; SBI-0051101.P002; AB1002120; ST2409585; Taurine, Vetec(TM) reagent grade, >=99%; TR-001805; A0295; AM20080018; B1846; EU-0101134; FT-0611241; T-130; C00245; D00047; T 0625; AB00443712-07; AB00443712_09; AB00443712_10; Q207051; J-508042; SR-01000076144-1; SR-01000076144-3; SR-01000076144-5; Taurine, certified reference material, TraceCERT(R); F2191-0280; Z1317839154; Taurine, cell culture tested, meets USP testing specifications; Taurine, United States Pharmacopeia (USP) Reference Standard; Taurine, Pharmaceutical Secondary Standard; Certified Reference Material; 91105-79-2; Taurine, PharmaGrade, Ajinomoto, Manufactured under appropriate GMP controls for pharma or biopharmaceutical production, suitable for cell culture; AI3-18307
Tea tree oil Oils, tea tree; T36-C7
Tecloftalam 2,3,4,5-Tetrachloro-6-[[(2,3-dichlorophenyl)amino]carbonyl]benzoic acid; Techlofthalam; 6-(((2,3-Dichlorophenyl)amino)carbonyl)-2,3,4,5-tetrachlorobenzoic acid
Teniposide (5R,5aR,8aR,9S)-5,8,8a,9-Tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-O-[(R)-2-thienylmethylene]-beta-D-glucopyranosyl]oxy]furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one; Teniposide; CCRIS 2058